US20230331842A1 - Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof - Google Patents

Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof Download PDF

Info

Publication number
US20230331842A1
US20230331842A1 US18/317,076 US202318317076A US2023331842A1 US 20230331842 A1 US20230331842 A1 US 20230331842A1 US 202318317076 A US202318317076 A US 202318317076A US 2023331842 A1 US2023331842 A1 US 2023331842A1
Authority
US
United States
Prior art keywords
seq
antibodies
iglv3
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/317,076
Inventor
Marcus DUHREN-VON MINDEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinabiosolution GmbH
Original Assignee
AVA Lifescience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVA Lifescience GmbH filed Critical AVA Lifescience GmbH
Priority to US18/317,076 priority Critical patent/US20230331842A1/en
Publication of US20230331842A1 publication Critical patent/US20230331842A1/en
Assigned to SINABIOSOLUTION GMBH reassignment SINABIOSOLUTION GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AVA LIFESCIENCE GMBH
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21 R110 ).
  • BCR B-cell receptor
  • IGLV3-21 R110 R110-mutated immunoglobulin lambda variable 3-21
  • Antibody therapeutics have been proven to be very effective reagents for the treatment of Leukemias and Lymphomas originating from malignant transformations of B-lineage cells. Since the approval of monoclonal antibodies such as Rituximab, response rates, long-term outcomes, and life-quality of patients with CLL have remarkably improved.
  • CLL is a heterogeneous, B-lymphocyte-derived malignancy resulting from the clonal proliferation of a CD5-positive subpopulation of B lymphocytes which progressively accumulate in the bone marrow, lymph nodes, peripheral blood and spleen (Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995; 333: 1052-1057).
  • the disease is the most common type of leukemia in western countries and typically occurs in elderly patients, with a two-fold increased risk of developing CLL for men compared to women (Kipps T J, Stevenson F K, Wu C J, Croce C M, Packham G, Wierda W G, et al. Chronic lymphocytic leukemia. Nat Rev Dis Primers (2017) 3:1-12).
  • BCR is one of the major factors in clonal selection and survival of CLL cells as reviewed by Burger and Chiorazzi (Burger J A, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601).
  • the BCR is a multiprotein structure that is composed of an antigen binding subunit and a signaling subunit, which are non-covalently associated.
  • the antigen-binding subunit consists of a membrane immunoglobulin containing two identical heavy chains and two identical light chains with one constant domain in each light chain and three in each heavy chain. Each heavy chain associates with a light chain to form an antigen-binding site. Each light and each heavy chain contains a variable domain forming the antigen-binding site.
  • the immunoglobulin genes encoded in the Igh, Igl and Igk loci contain large numbers of V (variable), D (diversity) and J (joining) gene segments upstream of one or more constant exons.
  • immunoglobulin gene rearrangement randomly assembles V, D and J gene segments to create a complete V exon in the Igh locus, and V and J gene segments in either the Igk or Igl locus.
  • V and J gene segments in either the Igk or Igl locus.
  • SHM somatic hypermutation
  • the BCR's signal transduction moiety is composed of a disulfide-linked heterodimer of the Ig ⁇ and Ig ⁇ (CD79a/CD79b) proteins.
  • Ig ⁇ and Ig ⁇ each contain a single immunoreceptor tyrosine-based activation motif (ITAM) within their cytoplasmic tail that initiates signal transduction following BCR aggregation upon antigen-binding (Flaswinkel, H., Reth, M., 1994. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 13, 83-89).
  • ITAM immunoreceptor tyrosine-based activation motif
  • Antigen-binding rapidly activates the Src family kinase Lyn leading to the phosphorylation of Ig ⁇ /Ig ⁇ . This initiates the formation of a large signaling complex on the cytoplasmic side of the membrane composed of the BCR, various tyrosine kinases, adaptor proteins, and signaling enzymes.
  • Proximal BCR signaling is mediated by the protein tyrosine kinase Syk (spleen tyrosine kinase), which is recruited to the phosphorylated ITAMs of Ig ⁇ and Ig ⁇ , leading to the propagation of the signal via association of Syk with the adaptor protein SLP65 and its downstream signaling enzymes Bruton's tyrosine kinase (BTK) and phospholipase C ⁇ 2 (PLC ⁇ 2).
  • Syk protein tyrosine kinase
  • BTK Bruton's tyrosine kinase
  • PLC ⁇ 2 phospholipase C ⁇ 2
  • Signals emanating the signaling complex activate downstream pathways, including calcium mobilization, phosphoinositide 3-kinases (PI3Ks), nuclear factor- ⁇ B (NF- ⁇ B), nuclear factor of activated T-cells (NF-AT), mitogen-activated protein kinases (MAPKs), and Rat sarcoma (RAS) signaling pathways (Burger J A and Chiorazzi N, 2013, s.a).
  • PI3Ks phosphoinositide 3-kinases
  • NF- ⁇ B nuclear factor- ⁇ B
  • NF-AT nuclear factor of activated T-cells
  • MAPKs mitogen-activated protein kinases
  • RAS Rat sarcoma
  • protein kinase Syk is constitutively phosphorylated through sustained BCR signaling, and several studies have revealed that also other key molecules of the signaling pathways downstream of BCR engagement in normal B cells, such as PKC, phosphoinositide 3-kinase and mitogen-activated protein kinase p38, are constitutively activated in B-CLL cells, resulting in the deregulation of the activity or expression of several prosurvival molecules and downstream pathways (Gobessi S, Laurenti L, Longo P G, Carsetti L, Berno V, Sica S et al.
  • PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation.
  • High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia.
  • NF-kB or PI3K/AKT Constitutively activated signaling pathways such as NF-kB or PI3K/AKT have been shown to lead to the transcription and overexpression of key antiapoptotic proteins, notably several members of the B-cell lymphoma 2 (Bcl-2) and inhibitor of apoptosis protein (IAP) families (Loeder S et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 2009; 69: 8977-8986).
  • Bcl-2 B-cell lymphoma 2
  • IAP inhibitor of apoptosis protein
  • Mcl-1 is a crucial player in impaired apoptosis in CLL cells, and BCR signals reportedly upregulate Mcl-1 expression through the PI3K/AKT pathway (Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov D G. Sustained signaling through the B-cell receptor induces McI-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005; 105: 4820-4827).
  • CLL patients with a mutated IGHV-gene M-CLL
  • CLL patients with an unmutated IGHV gene with a germline identity equal to or above 98% generally have a more indolent disease course than CLL patients with an unmutated IGHV gene with a germline identity equal to or above 98% (U-CLL).
  • U-CLL unmutated IGHV gene with a germline identity equal to or above 98%
  • IGHV3-21 usage according to subset #2 has always been observed in association with the expression of an immunoglobulin lambda variable 3-21 chain along with an acquired substitution of glycine with arginine at amino acid position 110 (IGLV3-21 R110 ) in the light chain.
  • Causative for the arginine 110 (R110) of IGLV3-21 R110 is a single G>C substitution on the splice site between the immunoglobulin lambda J and constant genes.
  • IGLV3-21 R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021; 137(21): 2935-2946).
  • the alleles IGLV3-21*01 (IMGT/LIGM-DB accession No. X71966) and IGLV3-21*04 (IMGT/LIGM-DB accession No. AC279208) encode for the prerequisite K16 and D50 and D52, with the last two incorporated into a motif that, in most cases studied, included a tyrosine at position 49 and a serine at position 51 of IGLV3-21 R110 (for an exemplarily IGLV3-21 R110 see FIG. 7 ).
  • the IGLV3-21 R110 CLL subgroup for which the name subset #2L has also been proposed, is associated with a very aggressive disease course. Indeed, the poor outcome of the IGLV3-21 R110 CLL cases is independent of IGHV mutational status or the nature of the heavy chain. Since IGHV3-21 R110 is found in mutated CLL such as subset #2 (see above) as well as in association with different heavy chains such as IGHV1-18, IGHV3-53 or IGHV3-64 (Nadeu et al. 2021, supra), the IGLV3-21 R110 defines a group of CLL that is neither limited to the conventional subset classification based on empirically defined epigenetic stereotypes nor to the IGHV-mutational status.
  • Idelalisip is an inhibitor of the hematopoetic cell restricted 5 iso-form of PI3K, which promotes apoptosis in primary CLL cells (Hoellenriegel J, Meadows S A, Sivina M, et al.
  • the phosphoinositide 3′-kinase delta inhibitor, CAL-101 inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118: 3603-3612).
  • Ibrutinib is an inhibitor of BTK that induces apoptosis in B-cell lymphomas and CLL-cells (Hermann S E, Gordon A L, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117: 6287-6296). More recent therapies are increasingly using monoclonal antibodies such as e.g. Alemtuzumab, which acts as a CD52 antibody, or Obinutuzumab, Rituximab, and Ofatumumab, which target the cell surface B-linage-restricted antigen CD-20.
  • monoclonal antibodies such as e.g. Alemtuzumab, which acts as a CD52 antibody, or Obinutuzumab, Rituximab, and Ofatumumab, which target the cell surface B-linage-re
  • the remission time can be extended by approximately 10 months.
  • state-of-the-art therapies for the treatment are usually very stressful for the patient, since the drug targets are critical to the survival of both normal and malignant B cells, and low blood counts, including low levels of certain white blood cells (neutropenia), are common side effects.
  • chemotherapeutics a high infection risk, latent infections and off-target effects to immune system have been reported as further side effects.
  • the undesired side effects of the therapy and the often insufficient effect of the drugs lead to a high death rate, because not only tumor cells, but also healthy cells of the immune system are damaged.
  • WO 2019/008129 discloses antibodies that can be used to remove CLL cells from blood samples.
  • the antibodies of WO 2019/008129 have been expressed as IgG antibodies in a hybridoma cell line departing from a murine host.
  • WO 2019/008129 discloses the respective variable heavy- and light-chain domains of such antibodies only.
  • the present invention solves the above problem, by providing in a first aspect an antibody having a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2, or a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or an antibody comprising a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 in any combination with a variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • IGLV3-21 R110 is the light chain variable region of the BCR, that enables BCR-BCR interactions, to induce an autonomously active BCR.
  • Structurally such IGLV3-21 R110 is characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein in any case at position 110 of said sequence there is Arginine and not Glycin.
  • a “variant” of an antibody or antigen-binding fragment contemplated in the invention is a molecule in which the binding activity of the antibody or antigen-binding fragment for IGLV3-21 R110 is maintained.
  • a “humanized” antibody is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; (ii) where amino acids of the framework regions of a non-human antibody are partially exchanged to human amino acid sequences by genetic engineering or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.
  • a non-human source e.g., a transgenic mouse which bears a heterologous immune system
  • CDR-grafted wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.
  • variable domains are derived from a non-human origin and some or all constant domains are derived from a human origin.
  • the term “monoclonal” antibody as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the term “monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins. The term “monoclonal” is not to be construed as to require production of the antibody by any particular method. The term monoclonal antibody specifically includes murine, chimeric and humanized antibodies.
  • an antibody “binds specifically to”, is “specific to/for” or “specifically recognizes” an antigen of interest, e.g. a tumor-associated polypeptide antigen target (here, IGLV3-21 R110 ), is able to discriminate between such antigen and one or more reference antigen(s).
  • a tumor-associated polypeptide antigen target here, IGLV3-21 R110
  • “specific binding”. “binds specifically to”, is “specific to/for” or “specifically recognizes” is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Flow cytometry, Western blots, ELISA-, RIA-, ECL-, IRMA-, immunohistological-tests and peptide scans.
  • Binding affinity or “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule and its binding partner. Unless indicated otherwise, as used herein, “binding affinity” or “Affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g. an antibody and an antigen).
  • Dissociation rate constant K D are usually calculated based on the ratio of equilibrium association (k a ) and dissociation rate (k d ) constants. The dissociation constant “K D ” is commonly used to describe the affinity between a molecule (such as an antibody) and its binding partner (such as an antigen) i.e.
  • Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules.
  • the term “high affinity” means, that the antibody binds to IGLV3-21 R110 -positive CLL BCR with an affinity (KD) of lower than or equal to 10 ⁇ 9 M (monovalent affinity).
  • KD affinity
  • the antibody may have substantially greater affinity for the target antigen compared to other unrelated molecules. Affinity can be measured by common methods known in the art, e.g. according to Example 5.
  • epitopic determinants includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptors.
  • Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains, or combinations thereof and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • an “isolated” antibody is one that has been identified and separated from a component of the cell that expressed it. Contaminant components of the cell are materials that would interfere with diagnostic or therapeutic uses of the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes.
  • the antibody is purified (1) to greater than 95% by weight of antibody as determined e.g.
  • ADCC antibody-dependent cell-mediated cytotoxicity
  • Fc ⁇ Rs Fc gamma receptors
  • cytotoxic cells e.g. NK cells, neutrophils, and macrophages
  • “Complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass), which are bound to their cognate antigen.
  • C1q first component of the complement system
  • a CDC assay e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996), may be performed.
  • Polypeptide variants with altered Fc region amino acid sequences polypeptides with a variant Fc region
  • increased or decreased C1q binding are described, e.g., in U.S. Pat. No. 6,194,551 BI and WO 1999/51642.
  • Percent (%) sequence identity with respect to a reference polynucleotide or polypeptide sequence, respectively, is defined as the percentage of nucleic acid or amino acid residues, respectively, in a candidate sequence that are identical with the nucleic acid or amino acid residues, respectively, in the reference polynucleotide or polypeptide sequence, respectively, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Conservative substitutions are not considered as part of the sequence identity. Preferred are un-gapped alignments.
  • the antibodies of the present invention are based on the discovery of a novel murine antibody that has a specific affinity for BCRs harboring IGLV3-21 R110 and that can deliver a therapeutic benefit to a subject.
  • the antibodies and their beneficial properties enabling therapeutic activity are described in more detail hereinafter.
  • these antibodies strongly activate the IGLV3-21 R110 -BCR. More specifically these antibodies lead to a strong phosphorylation of Syk, BTK, and PI3K on the short term, which induces apoptosis and thus finally inhibits tumor growth in vivo.
  • the antibody “mAb01-01” is therefore a first preferred embodiment of the first aspect of the present invention, which is characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
  • the antibody “HC0-LC0” is therefore a second preferred embodiment of the first aspect of the present invention, which is characterized by a heavy chain corresponding to SEQ ID NO: 11 and a light chain corresponding to SEQ ID NO: 12.
  • the antibody “HC6-LC6” is therefore a third preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 16.
  • an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
  • the antibody “HC6-LC7” is therefore a fourth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 17.
  • the antibody “HC6-LC8” is therefore a fifth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 18.
  • an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
  • the antibody “HC6-LC9” is therefore a sixth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 19.
  • an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
  • an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
  • the antibody “HC7-LC7” is therefore an eighth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 17.
  • the antibody “HC7-LC8” is therefore a ninth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 18.
  • an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
  • a variant can include, for example, an antibody that has at least one altered complementary determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-a-vis a peptide sequence disclosed herein.
  • CDR complementary determining region
  • FR framework
  • An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs (complementarity determining regions).
  • the antigen-binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and, hence, play an important role in antigen binding.
  • the skilled worker routinely can generate mutated or diversified antibody sequences.
  • the skilled worker can use the sequences of the antibodies provided herein (e.g. of Table 1 and/or Table 2) to design peptide variants that are within the scope of the present invention.
  • variants may be obtained by using one antibody of this first aspect of the invention as starting point for optimization by diversifying one or more amino acid residues in the antibody, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekiis B. et al., Nucl. Acids Res. 1994, 22: 5600.).
  • TAM trinucleotide mutagenesis
  • Antibodies include molecules with modifications/variations including but not limited to e.g. modifications leading to altered half-life (e.g. modification of the Fe part or attachment of further molecules such as PEG), altered binding affinity or altered ADCC or CDC activity.
  • Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, “conservative substitutions,” may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
  • nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, praline, phenylalanine, tryptophane, and methionine;
  • polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine;
  • positively charged (basic) amino acids include arginine, lysine, and histidine; and
  • negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d).
  • glycine and praline may be substituted for one another based on their ability to disrupt a-helices.
  • certain amino acids such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in p-pleated sheets.
  • Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns.
  • the third to tenth preferred embodiments of the antibodies pursuant to the first aspect of the present invention may also comprise a variable heavy chain which is at least 83.3%, 85%, 90%, 92%, 95% sequence identical to the variable heavy chain as presented by SEQ ID NO: 15, or at least 82.5%, 85%, 90%, 92%, 95% sequence identical to the variable heavy chain as presented by SEQ ID NO: 20.
  • the third to tenth preferred embodiments of the antibodies pursuant to the first aspect of the present invention may also comprise a variable light chain which is at least 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 16, or at least 87%, 90%, 92%, 95% identical to the variable light chain as presented by SEQ ID NO: 17, or at least 80.5%, 85%, 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 18, or at least 77.7%, 80%, 85%, 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 19.
  • All of the preferred embodiments of the antibodies pursuant to the first aspect of the present invention combine a variable heavy chain sequence comprising sequences as represented by SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2) and SEQ ID NO: 7 (H-CDR 3) with a variable light chain sequence comprising sequences as represented by SEQ ID NO: 8 (L-CDR 1), SEQ ID NO: 9 (L-CDR 2), SEQ ID NO: 10 (L-CDR 3).
  • the antibodies pursuant to the first aspect of the invention are preferably an IgG of any isotype (e.g., IgG 1 IgG 2 , IgG 3 , IgG 4 ).
  • Their respective antigen-binding fragments may be a Fab, Fab′, F(ab′)2 or scFv, for example.
  • the antibodies pursuant to the first aspect of the present invention are expressed as IgG1 isotype antibodies and are even more preferably humanized.
  • the most preferred antibodies of the first aspect of the present invention are those of the second, third and seventh embodiment (“HC0-LC0”, “HC6-LC6” and “HC7-LC6”), wherein amongst those the foremost preferred antibodies are those of the third and seventh embodiment (“HC6-LC6” and “HC7-LC6”).
  • All of the aforesaid preferred embodiments of the first aspect of the present invention are particularly advantageous, as they have been shown to display a very high affinity in the range of K D ⁇ 10 ⁇ 10 M, resulting in beneficial aspect of the present invention that they specifically, selectively and non-cross-reactive with other tissues of the CLL patient bind to the IGLV3-21 R110 -harboring BCR and thereby enable selective killing of malignant B-cells.
  • All of the aforementioned embodiments of the first aspect of the invention selectively bind to IGLV3-21 R110 .
  • said IGLV3-21 R110 is in a generally preferred embodiment of this first aspect of the invention further characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein at position 16 of said sequence there is lysine and at positions 50 and 52 there are aspartates.
  • at position 49 there is a tyrosine and at position 51 there is a serine In a generally further more preferred embodiment of this first aspect of the invention at position 49 there is a tyrosine and at position 51 there is a serine.
  • the second aspect of the present invention pertains to the provision of the antibodies of the first aspect of the present invention for use in the treatment of CLL in IGLV3-21 R110 positive patients.
  • this second aspect of the present invention pertains to a method of treatment of CLL in IGLV3-21 R110 positive patients, by administering a therapeutically active amount of antibodies of the first aspect of the present invention.
  • the antibodies are therefore characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
  • the antibodies are characterized by a heavy chain corresponding to SEQ ID NO: 11 and a light chain corresponding to SEQ ID NO: 12.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 16.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 17.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 18.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 19.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 16.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 17.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 18.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 are more preferred.
  • the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 19.
  • antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 are more preferred.
  • these antibodies may selectively discriminate between the wild-type IGLV3-21 G110 variant and the malignant IGLV3-21 R110 variant and that treatment with these antibodies in a xenograft mouse model (see FIG. 5 and Example 9) results in significant depletion of human IGLV3-21 R110 -positive B-cells, resulting in amelioration of CLL.
  • an effective dose of such antibodies is well within the capability of those skilled in the art.
  • the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., neoplastic cells, or in animal models, usually mice, rabbits, dogs, pigs or monkeys.
  • the animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • a therapeutically effective dose refers to that amount of an antibody that ameliorates the symptoms or condition to be treated.
  • condition to be treated is a clinically manifest CLL, which is caused by aberrant proliferation of B-cells that have an autonomously active BCR.
  • the second aspect of the present invention addresses a clinically manifest CLL which is characterized by an aberrant proliferation of B-cells that have an autonomously active BCR harboring IGLV3-21 R110 .
  • All of the aforementioned embodiments of the second aspect of the invention pertain to the treatment of CLL in patients that are IGLV3-21 R110 positive.
  • said IGLV3-21 R110 is in a generally preferred embodiment of this second aspect of the invention further characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein at position 16 of said sequence there is lysine and at positions 50 and 52 there are aspartates.
  • at position 49 there is a tyrosine and at position 51 there is a serine In a generally further more preferred embodiment of this first aspect of the invention at position 49 there is a tyrosine and at position 51 there is a serine.
  • a therapeutically effective amount is therefore an amount of an antibody that is of sufficient quantity to deplete IGLV3-21 R110 -positive CLL cells in a treated area of a patient—either as a single dose or according to a multiple dose regimen, yet which amount is toxicologically tolerable.
  • the antibodies may also be co-administered with known medicaments. Therefore they may be administered as the sole pharmaceutical agent or in combination with one or more additional therapeutic agents where the combination causes no unacceptable adverse effects.
  • This combination therapy includes administration of a single pharmaceutical dosage formulation which contains antibodies pursuant to the first aspect of the invention and one or more additional therapeutic agents, as well as administration of an antibody of the first aspect of the invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.
  • the present invention also relates to the DNA molecules that encode an antibody of the first aspect of the invention.
  • Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the “binding” phase and the “washing” phase.
  • a method of generating variants is to start with one of the DNAs disclosed herein and then to conduct site-directed mutagenesis. See Ausubel et al., supra, chapter 8, Supplement 37 (1997).
  • a target DNA is cloned into a single-stranded DNA bacteriophage vehicle.
  • Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alteration(s).
  • the complementary strand is synthesized and the double stranded phage is introduced into a host.
  • Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing.
  • various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants.
  • this invention pertains to DNA molecules encoding a heavy chain of one the preferred antibodies of the first aspect of the present invention as represented by any sequence selected from the list consisting of SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 33 and SEQ ID NO: 38.
  • this invention pertains to DNA molecules encoding a light chain of one the preferred antibodies of the first aspect of the present invention as represented by any sequence selected from the list consisting of SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 and SEQ ID NO: 37.
  • Nucleic acids of the invention are suitable for recombinant production of antibodies using standard vectors and host cells containing a nucleic acid sequence of the invention.
  • the antibodies of the first aspect of the present invention that are used in the second aspect of the present invention may be co-administered with known medicaments.
  • the antibody might be co-administered with any general anti-B-cell antibodies.
  • the present invention also relates to compositions comprising the antibodies according to any of the embodiments of the first aspect of the invention, which may be used analogously to the second aspect of the invention.
  • the invention therefore, includes a pharmaceutical composition comprising an antibody pursuant to the first aspect of the invention alone or in combination with at least one other agent and a pharmaceutically acceptable carrier or excipient.
  • the other agent may be for instance a stabilizing compound and such at least one other agent and the antibody according to the first aspect of the invention may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • a preferred pharmaceutical composition is made up from a lyophilized powder of the antibody according to the first aspect of the invention in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.
  • compositions comprising an antibody of the invention formulated in an acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition.
  • the present invention also relates to such pharmaceutical compositions for use of CLL in IGLV3-21 R110 positive patients.
  • this related aspect of the present invention pertains to a method of treatment of CLL in IGLV3-21 R110 positive patients, by administering a therapeutically active amount of said such pharmaceutical compositions.
  • Such administration is usually accomplished parenterally.
  • Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.
  • compositions for parenteral administration include aqueous solutions of active compounds.
  • the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline.
  • Aqueous injection suspensions may contain substances that increase viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • suspensions of the active compounds may be prepared as appropriate oily injection suspensions.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • penetrants appropriate to the particular barrier to be permeated are used in the formulation.
  • penetrants are generally known in the art.
  • the invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.
  • Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.
  • kits may contain DNA sequences encoding the antibodies pursuant to the third aspect of the invention.
  • the DNA sequences encoding these antibodies are provided in a plasmid suitable for transfection into and expression by a host cell.
  • the plasmid may contain a promoter (often an inducible promoter) to regulate expression of the DNA in the host cell.
  • the plasmid may also contain appropriate restriction sites to facilitate the insertion of other DNA sequences into the plasmid to produce various antibodies.
  • the plasmid may also contain numerous other elements to facilitate cloning and expression of the encoded proteins. Such elements are well known to those of skill in the art and include, for example, selectable markers, initiation codons, termination codons, and the like.
  • the invention therefore further relates to the aforementioned packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention for use in the treatment of CLL in IGLV3-21 R110 positive patients.
  • FIGS. 1 A and 1 B were made from a 1:1 cell mix comprising IGHV3-21/IGLV3-21 R110 BCR positive TKO mouse cells and TKO cells lacking a BCR (cell mix A) stained with the above fluorescence labelled antibodies, while the plots in FIGS. 1 C and 1 D were made from a 1:1 cell mix comprising IGHV3-21/IGLV3-21 G110 BCR positive TKO mouse cells and TKO cells lacking a BCR (cell mix B).
  • FIGS. 1 B and 1 D nearly the half of the analysed TKO cells are positively stained with the respective anti-IgM antibodies, indicating that they possess a BCR, which is consistent with the expression of the BCR on the surface of approximately 50% of the TKO cells of the respective cell mixes.
  • the antibody of the present invention “mAb01-01” only recognizes the malignant variant of IGLV3-21 bearing the R110 mutation.
  • FIGS. 2 A to 2 F show FACS plots of human PBMC's processed pursuant to Example 6.
  • FIGS. 2 A and 2 D show FSC-SSC representations of said PBMC's in which a gate has been set likewise to FIGS. 1 A and 1 C to apparently living cells.
  • the gated cells are plotted to have anti-CD19-VioBright515 over anti-CD5-PE-C ⁇ 5 ( FIGS. 2 B and 2 E ) as well as anti-CD19-VioBright515 over mAb01-01-APC ( FIGS. 2 C and 2 F ).
  • FIGS. 2 A to 2 C depict an analysis of human PBMC's of a patient that was positively diagnosed of having B-cells expressing an IGHV4-39/IGLV3-21 R110 -BCR and FIGS. 2 D to 2 F depict the same analysis of human PBMC's of a patient whose CLL is not characterized by a IGHV3-21 R110 -BCR (i.e. non-IGLV3-21 R110 CLL).
  • FIGS. 2 B and 2 D CD5/CD19 ++ B-cells could be resolved and further comparison between the two patients samples ( FIGS. 2 C and 2 F ) shows that mAb01-01 selectively identified IGLV3-21 R110 -positive CLL B-cells only, allowing the differentiation between CLL types.
  • FIG. 3 shows a comparative binding kinetic of the antibodies HC0-LC0, HC6-LC6 and HC7-LC6 pursuant to the present invention and in accordance with Example 7. As can be seen, these three antibodies display essentially the same binding kinetic and have a near to identical binding specificity latest at 10 ⁇ g/ml concentration.
  • FIG. 4 shows a comparison of (left column) tissues stained with mAb01-01 and an anti-IgG against such mAb01-01 (sandwich-assay) against sole treatment of the same tissue samples solely with anti-IgG (right column) pursuant to Example 8.
  • the top row shows the respective result in a tissue sample of a CLL patient that is IGLV3-21 R110 -positive, while the lower rows show results in healthy donor samples.
  • FIG. 5 shows the absolute number of CLL cells in the spleen upon termination of the experiment pursuant to Example 9.
  • a xenograft mouse model artificially suffering from IGLV3-21 R110 -positive CLL was treated with a (pharmaceutically inactive) control (Group A), an amount of 0.3 mg/kg (Group B), an amount of 5 mg/kg (Group C) and 10 mg/kg (Group D) bodyweight of mAb01-01.
  • a (pharmaceutically inactive) control Group A
  • Group B an amount of 0.3 mg/kg
  • Group C an amount of 5 mg/kg
  • Group D 10 mg/kg bodyweight of mAb01-01.
  • all treatments result in a depletion of CLL-cells in the spleen, while at 10 mg/kg the depletion is extraordinary significant.
  • the antibodies of the present invention indeed facilitate an efficacious treatment of CLL characterized by IGLV3-21 R110 -positive BCRs.
  • FIG. 6 shows a schematic representation of BCR-BCR homotypic interaction of IGLV3-21 R110 light chains (as described by Minici et al.).
  • Two neighbouring BCRs are depicted with antigen-binding subunit comprising heavy (HC) and light chains (LC), transmembrane domain (TM), well as the signaling subunit (SU) composed of disulfide-linked heterodimer of the Ig ⁇ and Ig ⁇ proteins (CD79a/CD79b).
  • Mutated arginine at position 110 (R) of one BCR interacts with a germline-encoded aspartate (D) at position 50 of an adjacent BCR.
  • a further interaction between the two BCRs is mediated by the germline-encoded amino acid residues lysine (K) at position 16 and aspartate (D) at position 52.
  • FIG. 7 shows schematic representations of IGLV3-21R 110 .
  • FIG. 7 A exemplarily IGLV3-21 R110 (SEQ ID NO: 53) in one-letter code. Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al. are marked in bold.
  • FIG. 7 B Line 1: Amino acid position in IGLV3-21 R110 .
  • Line 2 Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al.
  • Lines 3 to 5 Different variants of the YDSD-motif in comparison. Amino acids are depicted in 3-letter code.
  • FIG. 8 shows the sequences according to SEQ ID NOs: 1 to 53.
  • SEQ ID NOs: 1-10 show various sequences from the organism Mus musculus .
  • SEQ ID NOs: 11-48 show various synthetic construct sequences.
  • SEQ ID NOs: 49-53 show various sequences from the organism Homo sapiens.
  • a human cellular expression system based on HEK293T cells was used for the expression of such IgG 1 (SEQ ID NO: 49 for VH, and SEQ ID NO: 50 for LC) as previously described, e.g. in Rekombinante AntiMech, Lehrbuch und Kompendium für resist undtechnik, 2. Auflage, Springer Verlag 2019.
  • a polyethyleneimine (PEI) based protocol was used for transfection. After several passages, the supernatant was pooled and the medium contained in the combined cell supernatant was purified using Protein G columns. The purity and quality of the soluble IgG 1 was determined by Western blotting.
  • the screening for positive clones was not performed by enzyme linked immunosorbent assay (ELISA) as usual. Since the target structure is a membrane-bound receptor, it is of central importance to validate the binding of the potential antibodies in a cellular system, i.e. while largely preserving the cell physiological states native to this cell type.
  • ELISA enzyme linked immunosorbent assay
  • groups of pooled supernatants were examined for binding events using fluorescence activated cell sorting (FACS) analysis.
  • FACS fluorescence activated cell sorting
  • TKO triple knockout
  • the starting point for the production of TKO cells is formed by transgenic mice which have a respective knockout for the genes Lambda5, RAG1 or RAG2 and SLP65 (Dlicken von Minden et al., 2012, Nature 489, p. 309-313).
  • the combination of the knockouts of RAG2 or RAG1 and Lambda5 leads to a blockade in the transition from the pro-B cell stage to the pre-B cell stage, which is classically characterized by the beginning rearrangement of the VDJ segments of the heavy chain (HC). Therefore they are pro-/pre-B cells.
  • the activity of the BCR can be measured by reconstitution with the inducible SLP65.
  • the production of such mice is known to the expert and belongs to the state of the art.
  • the bone marrow of the femur was extracted from the mice after they had been sacrificed.
  • the cells obtained in this way were then cultured under conditions that promote the survival of pro-/pre-B cells (37° C., 7.5% CO2, Iscoves medium, 10% FCS, P/S, murine IL7).
  • FACS sorting was carried out for control purposes, the pro-/pre-B cells were sorted and then returned to culture.
  • the markers used for this purpose are known to the specialist.
  • two different BCR-expressing TKO cell lines were generated, one of which expressed the membrane-bound IGHV3-21/IGLV3-21 R110 BCR.
  • the codon for the arginine at position 110 of the DNA encoding IGLV3-21 R110 was reverted to the germline sequence by well-known site-directed mutagenesis technique (see, e.g. Sambrook et al., 1989 supra).
  • the resulting TKO cells expressed a BCR containing IGLV3-21 with glycine at amino acid position 110 (IGLV3-21 G110 ).
  • spinfection with an empty expression vector was performed.
  • the function of the expressed BCRs could be characterized and the autonomously active state of the IGHV3-21/IGLV3-21 R110 BCR on the surface could thus be verified before selection.
  • the method of choice here is the measurement of Ca-flux after induction of SLP65 using FACS analysis and the use of a Ca 2+ dependent dye such as Indo-1. These methods are known to the expert (see M. Dschreiben-von Minden et. al; Nature 2012). With these cells as “targets”, FACS has now been used to identify an antibody that specifically binds to IGLV3-21 R110 -harboring BCRs. The first step was to identify the supernatants whose antibodies showed a binding.
  • mRNA was isolated from the individual hybridoma clone, cDNA was generated and amplified by Anchor PCR (Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, Skerra A, Veelken H. J Immunol Methods 1999 Oct. 29; 229(1-2):141-53).
  • Anchor PCR Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, Skerra A, Veelken H. J Immunol Methods 1999 Oct. 29; 229(1-2):141-53).
  • the sequence of the cDNA encoding the monoclonal antibody mAb01-01 was confirmed by Sanger sequencing (SEQ ID NO: 25 for HC nucleotide, SEQ ID NO: 26 for LC nucleotide) and placed into a vector suitable for expression in CHO cells.
  • IgG1 subtype Expression of the mAb01-01 as IgG1 subtype was verified using secondary anti-murine IgG1-APC and IgG2-APC antibodies. For this purpose, IGHV3-21/IGLV3-21 R110 -expressing TKO cells were stained in one batch with the secondary antibody alone and in another batch with mAb01-01 and the secondary antibody. Subsequent FACS analysis confirmed that the antibody had been expressed as IgG1.
  • the specific monoclonal antibody mAb01-01 was sequenced.
  • the following amino acid sequences were determined as depicted in Table 1: SEQ ID NO: 1 for the HC, SEQ ID NO: 2 for the LC, SEQ ID NO: 3 for the VH, SEQ ID NO: 4 for the VL.
  • the sequences corresponding to complementarity determining regions (CDR) of the heavy chain, H-CDR1, H-CDR2 and H-CDR3 are included in SEQ ID NOS: 5, 6 and 7, while the sequences corresponding to the light chain CDRs, L-CDR1, L-CDR2 and L-CDR3 are included in SEQ ID NOS: 8, 9 and 10.
  • VH and VL nucleotide sequences SEQ ID NO: 27 for VH Nucleotide, and SEQ ID NO: 28 for VL Nucleotide
  • VH sequence was fused with a human IgG1 isotype constant domain sequence (SEQ ID NO: 31 for IgG1 constant Nucleotide) and the VL sequence was fused with a human Ig ⁇ isotype constant domain (SEQ ID NO: 32 for Ig ⁇ constant Nucleotide) by PCR and expressed using a CHO based transient expression system.
  • the resulting antibody containing cell culture supernatant was clarified by centrifugation and filtration.
  • the chimeric antibody was purified from cell culture supernatant via affinity chromatography.
  • the purity of the antibody was determined to be >95%, as judged by reducing and denaturing Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE).
  • SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
  • the antibody was analyzed for protein content and concentration via Seize Exclusion Chromatography (SEC) in PBS-buffer. All steps were performed with state-of the-art equipment and techniques.
  • Humanization of mAb01-01 was carried out by in silico grafting the murine CDR's into mature human antibody frameworks using standard CDR-grafting technologies by Fusion Antibodies Plc, Harbor, N. Ireland. Key residues important for the VH/VL interface and canonical loop structure have been maintained as much as possible in the humanized variants using the CDRx platform (Fusion Antibodies Plc, Harbor, N. Ireland). Subsequently, the amino acid sequences of the humanized variants generated by fusion antibodies were converted to nucleotide sequences using Geneiouse software (Geneious Prime 2, Auckland, New Zealand).
  • VH sequences with a human IgG1 isotype constant domain sequence SEQ ID NO: 31 for IgG1 constant Nucleotide
  • VL sequences with a human Ig ⁇ isotype constant domain SEQ ID NO: 32 for Ig ⁇ constant Nucleotide
  • 16 pairs of the humanized heavy and light chains were generated, and the antibody gene sequences expressed transiently in Chinese Hamster ovary cells (CHO).
  • expressed humanized antibodies were purified from the cell culture supernatant and analyzed as described in Example 2 for HC0-LC0. Eight humanized antibodies as depicted in Table 2 were successfully yielded.
  • Example 1 The specificity of the antibody mAb01-01 observed in the selection (Example 1) was verified in a FAGS assay using the antibody coupled to a fluorescent marker.
  • cell mix A and cell mix B were prepared and subsequently stained with mAb01-01-APC (mAb01-01 was coupled with fluorescent marker APC by Immunotools GmbH).
  • mAb01-01 was coupled with fluorescent marker APC by Immunotools GmbH.
  • each batch was additionally stained with anti-IgM antibody (Anti-human IgM-PE, Clone: MHM-88, BioLegend Cat-No.: 314508).
  • Cell mix A was prepared at a 1:1 ratio of IGHV3-21/IGLV3-21 R110 B-cell receptor expressing TKO cells and B-cell receptor negative (empty vector; control) TKO cells in PBS buffer (Gibco, pH 7.2, Cat. no. 20012-019).
  • Cell mix B was prepared at a 1:1 ratio of IGHV3-21/IGLV3-21 G110 B-cell receptor expressing TKO cells and B-cell receptor negative (empty vector; control) TKO cells in PBS buffer.
  • Cells of cell mix A or B were suspended at approximately 106 cells per FACS tube in dilutions of the antibodies (5 ⁇ g/ml mAb01-01-APC, 2 ⁇ g/ml Anti-human IgM-PE, in a total volume of 100 ⁇ l) in PBS buffer, and incubated for 15 min at 4° C. in the dark. In the following, cells were washed once with 1 ml cold PBS buffer, resuspended in 200 ⁇ L cold PBS buffer.
  • TKO-cells of cell mix A or cell mix B were gated in a side scatter (SSC) vs. forward scatter (FSC) and the gated TKO-cells were analysed in anti-IgM-PE vs. mAb01-01-APC dot-plot to enumerate the different TKO-cell populations using quadrant stats.
  • SSC side scatter
  • FSC forward scatter
  • mAb01-01 binds to murine TKO cells expressing human IGLV3-21 R110 -BCR, whereas no binding occurs to human IGLV3-21 G110 -BCR expressing TKO mouse cells.
  • a soluble recombinant version of the BCR (170.5 kDa; sequence according to SEQ ID NO: 51 for HC and 52 for LC) was produced in 293-HEK cell line as monomeric human IgM by transient expression using a protocol described in Example 1, and binding to immobilized anti-IGLV3-21 R110 antibodies was monitored by Bio-Layer Interferometry (BLI) on a Fortebio Octet instrument (Satorius).
  • Kinetic assays were performed by first immobilizing the anti IGLV3-21 R110 antibodies onto biosensors through an indirect capturing reagent, anti-human IgG Fc antibody.
  • Anti IGLV3-21 R110 antibodies were loaded at a concentration of 0.01875 ⁇ g/ml to generate an anti IGLV3-21 R110 antibody capture level of between 0.30 and 0.34 nm.
  • a 9 nM BCR-fragment solution in running buffer (PBS, 0.02% Tween20, 0.1% BSA, 0.05% sodium acide) was prepared and serial diluted 1:3 to obtain 7 concentrations from 9 to 0.012 nM (9 nM, 3 nM, 1 nM, 0.333 nM, 0.111 nM, 0.037 nM, and 0.012 nM).
  • the anti IGLV3-21 R110 antibody capture biosensors were then submerged in wells containing the different concentrations of the soluble BCR-fragment for 900 seconds (association stage) followed by a dissociation step of 1200 seconds in running buffer. Steps were performed at a constant shake speed of 1000 rpm. All reagents were used as described by the manufacturer.
  • chimeric antibody HC0-LC0 binds with a K D value around 120 nM the soluble IGLV3-21 R110 B-cell receptor.
  • the humanized antibodies HC6-LC6 and HC7-LC6 exhibit binding characteristics similar to that of chimeric antibody HC0-LC0, exhibiting dissociation constants within 2-fold of the chimeric antibody HC01 LC01.
  • K D values of all humanized antibodies see Table 3.
  • the tissue sections Prior to IHC, the tissue sections were deparaffinized and hydrated. To unmask the antigens, microwave treatment with citrate buffer pH 6.0 (9 ml citric acid (0.1M) and 41 ml sodium citrate (0.1 M)) was performed. For this, the sections were boiled in the bubbling citrate buffer for 15 min, after which they chilled at room temperature for 30 min and then they were rinsed in PBS 3 ⁇ 5 min.
  • the slides were incubated for 2 hr with the first antibody at a dilution of 1:200 at RT in a humidity chamber. As a control, sections of all tissues were incubated under identical conditions without the first antibody. Thereafter, the slides were washed in PBS 3 ⁇ 5 min.
  • HRP horseradish peroxidase
  • T cells where separated by using Miltenyi CD3 Beads (Miltenyi Biotec) following the instruction for use provided by the manufacturer. T cells were cultured and expanded for 7 days using CD3/CD28 dynabeads (DynabeadsTM Human T-Activator CD3/CD28 for T Cell Expansion and Activation, Cat. No. 11161D, GIBCO) as described before (Qi J et al. Methods, 2019 s.a.).
  • mice After 7 days, the activated T cells and PBMCs (20 ⁇ 10 6 CLL PBMCs and 5 ⁇ 10 5 T cells per mouse) were injected i.v. into NSG mice.
  • mAb01-01 was given in different dosages i.p., twice a week for total 3 weeks, starting at week 2 post engraftment. Mice where pre-conditioned at the beginning of every week with 250 ⁇ l human serum. The mice were sacrificed after 3 weeks of treatment.
  • the spleen was isolated and analyzed for the existence of human IGLV3-21 R110 positive CLL B cells by flow cytometry using the mAb01-01 and antibodies against human CD45, CD5, and CD19 (CD5 IgG1 UCHT2, BioLegend; CD19 IgG1 HIB19, BD Biosciences; CD45 (human) IgG1 H130 Invitrogen).
  • flow cytometry cells were collected by centrifugation and resuspended in ice-cold 0.1% (w/v) BSA in PBS (flow cytometrybuffer). 100 ⁇ L containing 5 ⁇ 10 5 cells were distributed into a V-bottom 96-well plate (Corning).
  • the cells were first blocked with 5% (v/v) goat serum (Jackson ImmunoResearch) for 30 min on ice and then incubated with the indicated antibodies as recommended by the manufacturer. The cells were incubated for 30 min on ice in dark. Then the cells were washed twice with ice-cold flow cytometry buffer, resuspended in 200 ⁇ L flow cytometry buffer and analyzed using FACSCanto (BD Biosciences).
  • the treatment with mAb01-01 led to a reduction in tumor cell counts in all treated mice, and treatment with 10 mg/kg mAb01-01 reduced tumor growth supremely.

Abstract

The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110).The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.

Description

  • This application claims priority to EP22156205, filed Feb. 10, 2022, which is incorporated herein by reference in its entirety.
  • The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on Jan. 27, 2023, is named 32501_301701_SL.xml and is 66,075 bytes in size.
  • The present invention provides antibodies for the treatment of chronic lymphocytic leukemia (CLL). These antibodies target the B-cell receptor (BCR) of CLL cells characterised by R110-mutated immunoglobulin lambda variable 3-21 (IGLV3-21R110).
  • The invention also provides nucleic acid sequences encoding the forgoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    • BACKGROUND OF THE INVENTION
  • Antibody therapeutics have been proven to be very effective reagents for the treatment of Leukemias and Lymphomas originating from malignant transformations of B-lineage cells. Since the approval of monoclonal antibodies such as Rituximab, response rates, long-term outcomes, and life-quality of patients with CLL have remarkably improved.
  • CLL is a heterogeneous, B-lymphocyte-derived malignancy resulting from the clonal proliferation of a CD5-positive subpopulation of B lymphocytes which progressively accumulate in the bone marrow, lymph nodes, peripheral blood and spleen (Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995; 333: 1052-1057). The disease is the most common type of leukemia in western countries and typically occurs in elderly patients, with a two-fold increased risk of developing CLL for men compared to women (Kipps T J, Stevenson F K, Wu C J, Croce C M, Packham G, Wierda W G, et al. Chronic lymphocytic leukemia. Nat Rev Dis Primers (2017) 3:1-12).
  • Clinical and biological evidence has shown that the BCR is one of the major factors in clonal selection and survival of CLL cells as reviewed by Burger and Chiorazzi (Burger J A, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34: 592-601).
  • The BCR is a multiprotein structure that is composed of an antigen binding subunit and a signaling subunit, which are non-covalently associated. The antigen-binding subunit consists of a membrane immunoglobulin containing two identical heavy chains and two identical light chains with one constant domain in each light chain and three in each heavy chain. Each heavy chain associates with a light chain to form an antigen-binding site. Each light and each heavy chain contains a variable domain forming the antigen-binding site. The immunoglobulin genes encoded in the Igh, Igl and Igk loci contain large numbers of V (variable), D (diversity) and J (joining) gene segments upstream of one or more constant exons. In a developing B cell, immunoglobulin gene rearrangement randomly assembles V, D and J gene segments to create a complete V exon in the Igh locus, and V and J gene segments in either the Igk or Igl locus. Through combinatorial joining of gene segments, junctional diversity and random heavy and light chain pairing, each individual B cell progenitor generates its own and nearly unique antigen binding subunit, whose antigen-binding affinity can be further refined by somatic hypermutation (SHM).
  • The BCR's signal transduction moiety is composed of a disulfide-linked heterodimer of the Igα and Igβ (CD79a/CD79b) proteins. Igα and Igβ each contain a single immunoreceptor tyrosine-based activation motif (ITAM) within their cytoplasmic tail that initiates signal transduction following BCR aggregation upon antigen-binding (Flaswinkel, H., Reth, M., 1994. Dual role of the tyrosine activation motif of the Ig-alpha protein during signal transduction via the B cell antigen receptor. EMBO J. 13, 83-89).
  • Antigen-binding rapidly activates the Src family kinase Lyn leading to the phosphorylation of Igα/Igβ. This initiates the formation of a large signaling complex on the cytoplasmic side of the membrane composed of the BCR, various tyrosine kinases, adaptor proteins, and signaling enzymes. Proximal BCR signaling is mediated by the protein tyrosine kinase Syk (spleen tyrosine kinase), which is recruited to the phosphorylated ITAMs of Igα and Igβ, leading to the propagation of the signal via association of Syk with the adaptor protein SLP65 and its downstream signaling enzymes Bruton's tyrosine kinase (BTK) and phospholipase Cγ2 (PLCγ2). Signals emanating the signaling complex activate downstream pathways, including calcium mobilization, phosphoinositide 3-kinases (PI3Ks), nuclear factor-κB (NF-κB), nuclear factor of activated T-cells (NF-AT), mitogen-activated protein kinases (MAPKs), and Rat sarcoma (RAS) signaling pathways (Burger J A and Chiorazzi N, 2013, s.a).
  • Chronic activation of mature B cells through the B-cell receptor has been shown to be a key process in the formation and development of CLL (Stevenson F K, Krysov S, Davies A J, Steele A J, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia Blood. 2011; 118: 4313-4320). This agrees also with a study using EBV protein LMP2A as a constitutively active BCR surrogate, which showed that the development of a mouse B1 subset was dependent on a strong and prolonged BCR stimulation (Casola S, Otipoby K I, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004; 5: 317-27). Moreover, antigen-independent autonomous signalling of primary CLL B cells due to interactions of two neighbouring BCRs on a cell has been identified as a crucial driver of CLL development, resulting in elevated tyrosine phosphorylation of the BCR proximal signalling molecules, leading to periodic signalling and elevated Ca2+ mobilization (Dühren-von Minden M et al. Chronic lymphocytic leukemia is driven by antigen-independent cell-autonomous signalling. Nature. 2012; 489: 309-313).
  • It is well documented that protein kinase Syk is constitutively phosphorylated through sustained BCR signaling, and several studies have revealed that also other key molecules of the signaling pathways downstream of BCR engagement in normal B cells, such as PKC, phosphoinositide 3-kinase and mitogen-activated protein kinase p38, are constitutively activated in B-CLL cells, resulting in the deregulation of the activity or expression of several prosurvival molecules and downstream pathways (Gobessi S, Laurenti L, Longo P G, Carsetti L, Berno V, Sica S et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009; 23: 686-697. Ringshausen I, Schneller F, Bogner C, Hipp S, Duyster J, Peschel C et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase C delta. Blood 2002; 100: 3741-3748. Plate J M. PI3-kinase regulates survival of chronic lymphocytic leukemia B-cells by preventing caspase 8 activation. Leuk Lymphoma 2004; 45: 1519-1529. Sainz-Perez A, Gary-Gouy H, Portier A, Davi F, Merle-Beral H, Galanaud P et al. High Mda-7 expression promotes malignant cell survival and p38 MAP kinase activation in chronic lymphocytic leukemia. Leukemia 2006; 20: 498-504.).
  • Constitutively activated signaling pathways such as NF-kB or PI3K/AKT have been shown to lead to the transcription and overexpression of key antiapoptotic proteins, notably several members of the B-cell lymphoma 2 (Bcl-2) and inhibitor of apoptosis protein (IAP) families (Loeder S et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 2009; 69: 8977-8986). It is well established that in addition to Bcl-2 itself, Mcl-1 is a crucial player in impaired apoptosis in CLL cells, and BCR signals reportedly upregulate Mcl-1 expression through the PI3K/AKT pathway (Petlickovski A, Laurenti L, Li X, Marietti S, Chiusolo P, Sica S, Leone G, Efremov D G. Sustained signaling through the B-cell receptor induces McI-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood. 2005; 105: 4820-4827).
  • Different aspects of the BCR have been recognized to identify main CLL disease subtypes. For example, the level of somatic hypermutations within the variable region of the BCR immunoglobulin heavy chain (IGHV) has been used as a prognostic marker for decades. CLL patients with a mutated IGHV-gene (M-CLL), i.e. showing less than 98% IGHV gene identity with its closest germline, generally have a more indolent disease course than CLL patients with an unmutated IGHV gene with a germline identity equal to or above 98% (U-CLL). However, exceptions to this rule have been observed in which the mutational IGHV-gene status could not be correlated with a certain disease course. For example, cases using the IGHV3-21-gene, although mostly expressing a mutated BCR, had one of the worst clinical outcomes. A different approach, but also IGHV-determined, led to the categorization of around 30% of CLL cases into different prognostically important subsets, each with highly homogeneous biological features, clinical presentation and outcome. This categorization is based on the observation that, among mutated and unmutated cases, stereotyped BCRs carrying closely homologous heavy chain complementary determining region 3 (H-CDR3) sequences exist. Following this approach, the CLL cases characterized by the mutated IGHV3-21 could be assigned to the so-called Subset #2 (Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenic implications and clinical correlations. Blood. 2007; 109(1): 259-270; Agathangelidis A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: A molecular classification with implications for targeted therapies. Blood. 2012; 119: 4467-4475).
  • Notably, the IGHV3-21 usage according to subset #2 has always been observed in association with the expression of an immunoglobulin lambda variable 3-21 chain along with an acquired substitution of glycine with arginine at amino acid position 110 (IGLV3-21R110) in the light chain. Causative for the arginine 110 (R110) of IGLV3-21R110 is a single G>C substitution on the splice site between the immunoglobulin lambda J and constant genes. The presence of R110 together with germline encoded lysine 16 (K16) in one BCR, and aspartates (D) 50 and 52 in a tyrosineaspartate-serine-aspartate (YDSD) motif of a neighbour BCR, has been identified to enable BCR-BCR interactions, thus triggering cell-autonomous signalling (FIGS. 6 and 7 ; Minici, C. et al., Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukemia, Nature Comm. 2017; 8:15746).
  • In the course of epigenetic, genomic, and transcriptomic characterization of large cohorts of CLL patients focusing on the BCR light chain, it became clear that around 60% IGLV3-21R110 cases carried non-stereotyped BCR, emphasizing that subset #2 is just a minor subgroup of CLL characterized by IGLV3-21R110 (Stamatopoulos B, Smith T, Crompot E, et al. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. Clin Cancer Res. 2018; 24(20): 5048-5057. Nadeu F, Royo R, Clot G, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021; 137(21): 2935-2946).
  • Of the 4 alleles of the IGLV3-21 gene which have been identified in humans, the alleles IGLV3-21*01 (IMGT/LIGM-DB accession No. X71966) and IGLV3-21*04 (IMGT/LIGM-DB accession No. AC279208) encode for the prerequisite K16 and D50 and D52, with the last two incorporated into a motif that, in most cases studied, included a tyrosine at position 49 and a serine at position 51 of IGLV3-21R110 (for an exemplarily IGLV3-21R110 see FIG. 7 ). However, functionally equivalent variations in this motif have also been observed in IGLV3-21R110 CLL patients such as the replacement of the tyrosine with a phenylalanine or the serine with a threonine (Nadeu et al. 2021, s.a.; for the variants see also FIG. 7 ). Interestingly, the alleles IGLV3-21*01 and IGLV3-21*04 are strikingly underrepresented in B-cells of healthy donors, whereas all IGLV3-21 genes in patients studied by different groups could be assigned to allele IGLV3-21*01 or allele IGLV3-21*04 suggesting that these alleles might be mechanistically required for the development of the IGLV3-21R110 associated CLL.
  • The IGLV3-21R110 CLL subgroup, for which the name subset #2L has also been proposed, is associated with a very aggressive disease course. Indeed, the poor outcome of the IGLV3-21R110 CLL cases is independent of IGHV mutational status or the nature of the heavy chain. Since IGHV3-21R110 is found in mutated CLL such as subset #2 (see above) as well as in association with different heavy chains such as IGHV1-18, IGHV3-53 or IGHV3-64 (Nadeu et al. 2021, supra), the IGLV3-21R110 defines a group of CLL that is neither limited to the conventional subset classification based on empirically defined epigenetic stereotypes nor to the IGHV-mutational status. Moreover, the essential role of the R110 as a CLL driver mutation has been confirmed by site-specific mutagenesis experiments, which revealed that reversion of IGLV3-21R110 into IGLV3-21G110 resulted in abrogation of autonomous signalling capacity of the BCR (Stamatopoulos B, Smith T, Crompot E, et al. 2018, s.a.).
  • Studies correlating time-to-first treatment (TTFT) and overall survival (OS) with the presence of IGLV3-21R110-carrying BCR showed significant shorter values for patients expressing IGLV3-21R110 compared to patients with non-IGLV3-21R110 CLLs emphasizing a rapid need for therapy for IGLV3-21R110-positive patients (Nadeu F et al. 2021; s.a.).
  • The CLL in these patients is usually treated with chemotherapeutics such as Idelalisip and Ibrutinib, both as single agents and in combination with other drugs. Idelalisip is an inhibitor of the hematopoetic cell restricted 5 iso-form of PI3K, which promotes apoptosis in primary CLL cells (Hoellenriegel J, Meadows S A, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118: 3603-3612). Ibrutinib is an inhibitor of BTK that induces apoptosis in B-cell lymphomas and CLL-cells (Hermann S E, Gordon A L, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117: 6287-6296). More recent therapies are increasingly using monoclonal antibodies such as e.g. Alemtuzumab, which acts as a CD52 antibody, or Obinutuzumab, Rituximab, and Ofatumumab, which target the cell surface B-linage-restricted antigen CD-20. By using these antibodies, the remission time can be extended by approximately 10 months. However, state-of-the-art therapies for the treatment are usually very stressful for the patient, since the drug targets are critical to the survival of both normal and malignant B cells, and low blood counts, including low levels of certain white blood cells (neutropenia), are common side effects. Moreover, with regard to chemotherapeutics, a high infection risk, latent infections and off-target effects to immune system have been reported as further side effects. In general it can be summarized that the undesired side effects of the therapy and the often insufficient effect of the drugs lead to a high death rate, because not only tumor cells, but also healthy cells of the immune system are damaged.
  • From that, a specific treatment option for IGLV3-21R110-positive CLL patients that does not come along with the aforementioned side effects, still remains to be found.
  • Current investigations regarding potential antibodies targeting IGLV3-21R110 harboring BCRs mainly focus on diagnosis of this specific subtype of CLL. As a matter of example, Maity et al. describe immunophenotyping studies with an anti IGLV3-21R110 antibody that is used as prognostic marker for CLL. Said diagnostic anti-IGLV3-21R110 antibody is disclosed to be a IgG2a and Igκ antibody (Maity P C, Bilal M, Koning M T, et al. IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signalling. PNAS. 2020; 117(8): 4320-4327).
  • A first step forward towards opening up a treatment option is disclosed in WO 2019/008129, which discloses antibodies that can be used to remove CLL cells from blood samples. The antibodies of WO 2019/008129 have been expressed as IgG antibodies in a hybridoma cell line departing from a murine host. WO 2019/008129 discloses the respective variable heavy- and light-chain domains of such antibodies only.
  • WO 2019/008129 does not show that the antibodies disclosed therein are selective between healthy and diseased tissues nor that they have been applied in vivo. Thus any therapeutic effect thereof is not shown.
  • From the foregoing, a treatment option, particularly an antibody that is specific, selective and non-cross-reactive to other tissues, which would allow an improved treatment of CLL in IGLV3-21R110 positive patients is still unknown, but required.
    • SUMMARY OF THE INVENTION
  • The present invention solves the above problem, by providing in a first aspect an antibody having a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2, or a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or an antibody comprising a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 in any combination with a variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
  • Such antibody specifically, selectively and non-cross-reactive with other tissues of the CLL patient binds to the IGLV3-21R110-harboring BCR and thereby kills malignant B-cells. While recognizing the presence of the IGLV3-21R110-part of the BCR, this new antibody is also capable of treating “subset #2 CLL”, which is characterized by BCR's comprising an IGHV3-21/IGLV3-21R110-combination or any other CLL comprising IGLV3-21R110.
  • The provision of these antibodies results in a second aspect of the present invention, which is the provision of said antibodies for use in the treatment of CLL in IGLV3-21R110 positive patients. Likewise this second aspect of the present invention pertains to a method of treatment of CLL in IGLV3-21R110 positive patients, by administering a therapeutically active amount of said antibodies.
  • This is the first treatment option for CLL in IGLV3-21R110 positive patients, which enables selective killing of malignant B-cells without the side-effects that are associated with treatments offered by the state of the art. Even more so, the binding and killing of B-cells that are only characterized by the presence of an IGLV3-21R110-harboring BCR that was identified as a marker for CLL, makes such treatment independent of the requirement of such CLL to belong of any of the previously identified subsets of CLL that are defined by a certain IGHV.
  • Without being bound to a theory, the treatment with the antibodies of the present invention, is deemed to induce a hyper-activation of B-cells via the IGLV3-21R110 of the BCR in absence of a co-stimulatory signal. This finally results in the induction of apoptosis in the CLL cells bound by the antibodies. Therefore the treatment with the antibodies of the present invention is highly selective for malignant B-cells and amongst those even more selective for IGLV3-21R110 positive, B-cells.
  • In a third aspect the invention is also related to DNA molecules (nucleic acids) encoding the antibodies of the invention. Thus, the invention also relates to vectors and host cells containing a nucleic acid sequence of the invention.
    • Definitions
  • Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art to which this invention belongs. The following references, however, can provide one of skill in the art to which this invention pertains with a general definition of many of the terms used in this invention, and can be referenced and used so long as such definitions are consistent the meaning commonly understood in the art. Such references include, but are not limited to, Singleton et ah, Dictionary of Microbiology and Molecular Biology (2d ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); Hale & Marham, The Harper Collins Dictionary of Biology (1991); and Lackie et al., The Dictionary of Cell & Molecular Biology (3d ed. 1999); and Cellular and Molecular Immunology, Eds. Abbas, Lichtman and Pober, 2nd Edition, W.B. Saunders Company. Any additional technical resources available to the person of ordinary skill in the art providing definitions of terms used herein having the meaning commonly understood in the art can be consulted. For the purposes of the present invention, the following terms are further defined.
  • As used herein and in the appended claims, the singular forms “a,” “and,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to “a gene” is a reference to one or more genes and includes equivalents there of known to those skilled in the art, and so forth.
  • An “autonomously active” BCR is a special type of a permanently active BCR. While the conventional activation is based on an external antigen, the autonomously active BCR results from its interaction with membrane structures on the surface of the same cell. For the clinical picture of CLL, an autonomic activation-triggering interaction between BCRs adjacent to each other on the surface of the same cell could be shown (e.g. M. Dühren-von Minden et. al; Nature 2012).
  • IGLV3-21R110 is the light chain variable region of the BCR, that enables BCR-BCR interactions, to induce an autonomously active BCR. Structurally such IGLV3-21R110 is characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein in any case at position 110 of said sequence there is Arginine and not Glycin.
  • The term “antibody”, as used herein, is intended to refer to immunoglobulin molecules, preferably comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains which are typically inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region can comprise e.g. three domains CH1, CH2 and CH3. Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprised of one domain (CL). The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is typically composed of three CDRs and up to four FRs. arranged from amino terminus to carboxyterminus e.g. in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • As used herein, the term “Complementarity Determining Regions (CDRs; e.g., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain the presence of which are necessary for antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. The amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known schemes, including those described by Kabat et al. (“Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, M D, 1991; “Kabat” numbering scheme), Chothia and Lesk (J Mol Biol 196: 901-917 (1987)), and Lefranc et al. (“IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev. Comp. Immunol., 27:55-77, 2003; “IMGT” numbering scheme). Each complementarity determining region comprises amino acid residues as defined by IMGT. In some instances, a complementarity determining region can also include amino acids from a CDR region defined according to Kabat and/or a hypervariable loop according to Chothia numbering system.
  • Depending on the amino acid sequence of the constant domain of their heavy chains, intact antibodies can be assigned to different “classes”. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these maybe further divided into “subclasses” (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chain constant domains that correspond to the different classes of antibodies are called [alpha], [delta], [epsilon], [gamma], and [mu], respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.
  • As used herein the term “antibody” is understood to also include antigen-binding fragments and variants thereof. Thus, any reference to “antibody” in the context of the present invention is also a reference to an antigen-binding fragment and/or variant thereof, if not expressively stated otherwise, such as by specifying a full heavy or full light chain of an antibody that are combined to form said antibody.
  • An “antigen-binding fragment” hereby is defined as a fragment of an antibody/immunoglobulin (e.g., a variable region of an IgG) that retains the antigen-binding region. Antigen-binding fragments of the invention include Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; single domain antibodies (DAbs), linear antibodies; single-chain antibody molecules (scFv); and multispecific, such as bi- and tri-specific, antibodies formed from antibody fragments (C. A. K Borrebaeck, editor (1995) Antibody Engineering (Breakthroughs in Molecular Biology), Oxford University Press; R. Kontermann & S. Duebel, editors (2001) Antibody Engineering (Springer Laboratory Manual), Springer Verlag). An antibody other than a “multi-specific” or “multi-functional” antibody is understood to have each of its binding sites identical. The F(ab′)2 or Fab may be engineered to minimize or completely remove the intermolecular disulphide interactions that occur between the CH1 and CL domains.
  • An “antigen-binding region” of an antibody typically is found in one or more hyper variable region(s) of an antibody, e.g., the CDR1, -2, and/or -3 regions; however, the variable “framework” regions can also play an important role in antigen binding, such as by providing a scaffold for the CDRs.
  • A “variant” of an antibody or antigen-binding fragment contemplated in the invention is a molecule in which the binding activity of the antibody or antigen-binding fragment for IGLV3-21R110 is maintained.
  • A “humanized” antibody is defined herein as one that is (i) derived from a non-human source (e.g., a transgenic mouse which bears a heterologous immune system), which antibody is based on a human germline sequence; (ii) where amino acids of the framework regions of a non-human antibody are partially exchanged to human amino acid sequences by genetic engineering or (iii) CDR-grafted, wherein the CDRs of the variable domain are from a non-human origin, while one or more frameworks of the variable domain are of human origin and the constant domain (if any) is of human origin.
  • A “chimeric” antibody is defined herein as one, wherein the variable domains are derived from a non-human origin and some or all constant domains are derived from a human origin.
  • The term “monoclonal” antibody as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the term “monoclonal” indicates the character of the antibody as not being a mixture of discrete antibodies. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins. The term “monoclonal” is not to be construed as to require production of the antibody by any particular method. The term monoclonal antibody specifically includes murine, chimeric and humanized antibodies.
  • As used herein, an antibody “binds specifically to”, is “specific to/for” or “specifically recognizes” an antigen of interest, e.g. a tumor-associated polypeptide antigen target (here, IGLV3-21R110), is able to discriminate between such antigen and one or more reference antigen(s). In its most general form, “specific binding”. “binds specifically to”, is “specific to/for” or “specifically recognizes” is referring to the ability of the antibody to discriminate between the antigen of interest and an unrelated antigen, as determined, for example, in accordance with one of the following methods. Such methods comprise, but are not limited to Flow cytometry, Western blots, ELISA-, RIA-, ECL-, IRMA-, immunohistological-tests and peptide scans.
  • “Binding affinity” or “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule and its binding partner. Unless indicated otherwise, as used herein, “binding affinity” or “Affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g. an antibody and an antigen). Dissociation rate constant KD are usually calculated based on the ratio of equilibrium association (ka) and dissociation rate (kd) constants. The dissociation constant “KD” is commonly used to describe the affinity between a molecule (such as an antibody) and its binding partner (such as an antigen) i.e. how tightly a ligand binds to a particular protein. Ligand-protein affinities are influenced by non-covalent intermolecular interactions between the two molecules. The term “high affinity” means, that the antibody binds to IGLV3-21R110-positive CLL BCR with an affinity (KD) of lower than or equal to 10−9M (monovalent affinity). The antibody may have substantially greater affinity for the target antigen compared to other unrelated molecules. Affinity can be measured by common methods known in the art, e.g. according to Example 5.
  • As used herein, the term ‘epitope’ includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptors. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains, or combinations thereof and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
  • An “isolated” antibody is one that has been identified and separated from a component of the cell that expressed it. Contaminant components of the cell are materials that would interfere with diagnostic or therapeutic uses of the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody is purified (1) to greater than 95% by weight of antibody as determined e.g. by the Lowry method, IN-Vis spectroscopy or by SDS-Capillary Gel electrophoresis (for example on a Caliper LabChip GXII, GX 90 or Biorad Bioanalyzer device), and in further preferred embodiments more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated naturally occurring antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • The term “cancer” refers to the physiological condition or disease in which cells divide without control leading to unregulated cell growth. A “tumor” comprises one or more cancer cells.
  • “Antibody-dependent cell-mediated cytotoxicity” or “ADCC” refers to a form of cytotoxicity in which secreted Ig bound onto Fc gamma receptors (FcγRs) present on certain cytotoxic cells (e.g. NK cells, neutrophils, and macrophages) enable these cytotoxic effector cells to bind specifically to an antigen-bearing target cell and subsequently kill the target cell e.g. with cytotoxins.
  • “Complement dependent cytotoxicity” or “CDC” refers to the lysis of a target cell in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to antibodies (of the appropriate subclass), which are bound to their cognate antigen. To assess complement activation, a CDC assay, e.g., as described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996), may be performed. Polypeptide variants with altered Fc region amino acid sequences (polypeptides with a variant Fc region) and increased or decreased C1q binding are described, e.g., in U.S. Pat. No. 6,194,551 BI and WO 1999/51642.
  • “Percent (%) sequence identity” with respect to a reference polynucleotide or polypeptide sequence, respectively, is defined as the percentage of nucleic acid or amino acid residues, respectively, in a candidate sequence that are identical with the nucleic acid or amino acid residues, respectively, in the reference polynucleotide or polypeptide sequence, respectively, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Conservative substitutions are not considered as part of the sequence identity. Preferred are un-gapped alignments. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, LALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
    • DETAILED DESCRIPTION OF THE INVENTION First Aspect-of the Invention—Antibodies
  • The antibodies of the present invention are based on the discovery of a novel murine antibody that has a specific affinity for BCRs harboring IGLV3-21R110 and that can deliver a therapeutic benefit to a subject. The antibodies and their beneficial properties enabling therapeutic activity are described in more detail hereinafter.
  • The antibodies of the invention, which may be murine, humanized or chimeric, can be used in many contexts, which are more fully described herein.
  • According to the first aspect of the present invention, antibodies having a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2, or a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or antibodies comprising a variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 in any combination with a variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19 are provided.
  • These antibodies can be murine, humanized or chimeric antibodies and they specifically bind to the IGLV3-21R110-BCR with high affinity.
  • As outlined above, it is believed that these antibodies strongly activate the IGLV3-21R110-BCR. More specifically these antibodies lead to a strong phosphorylation of Syk, BTK, and PI3K on the short term, which induces apoptosis and thus finally inhibits tumor growth in vivo.
  • Preferred embodiments of the first aspect of the present invention are further characterized in more detail in Table 1 and Table 2 of the Examples.
  • The antibody “mAb01-01” is therefore a first preferred embodiment of the first aspect of the present invention, which is characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
  • The antibody “HC0-LC0” is therefore a second preferred embodiment of the first aspect of the present invention, which is characterized by a heavy chain corresponding to SEQ ID NO: 11 and a light chain corresponding to SEQ ID NO: 12.
  • The antibody “HC6-LC6” is therefore a third preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 16.
  • Within said third preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
  • The antibody “HC6-LC7” is therefore a fourth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 17.
  • Within said fourth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
  • The antibody “HC6-LC8” is therefore a fifth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 18.
  • Within said fifth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
  • The antibody “HC6-LC9” is therefore a sixth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 19.
  • Within said sixth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
  • The antibody “HC7-LC6” is therefore a seventh preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 16.
  • Within said seventh preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 is more preferred.
  • The antibody “HC7-LC7” is therefore an eighth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 17.
  • Within said eighth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 is more preferred.
  • The antibody “HC7-LC8” is therefore a ninth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 18.
  • Within said ninth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 is more preferred.
  • The antibody “HC7-LC9” is therefore a tenth preferred embodiment of the first aspect of the present invention, which is characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 19.
  • Within said tenth preferred embodiment of the first aspect of the invention, an antibody characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 is more preferred.
  • Antibodies of this first aspect of the invention are not limited to the specific peptide sequences provided. Rather, the invention also embodies variants. With reference to the instant disclosure and conventionally available technologies and references, the skilled worker will be able to prepare, test and utilize functional variants of the antibodies disclosed herein, while appreciating these variants having the ability to bind to the IGLV3-21R110-BCR and thereby killing the B-cell fall within the scope of the present invention.
  • A variant can include, for example, an antibody that has at least one altered complementary determining region (CDR) (hyper-variable) and/or framework (FR) (variable) domain/position, vis-a-vis a peptide sequence disclosed herein. To better illustrate this concept, a brief description of antibody structure follows.
  • An antibody is composed of two peptide chains, each containing one (light chain) or three (heavy chain) constant domains and a variable region (VL, VH), the latter of which is in each case made up of four FR regions and three interspaced CDRs (complementarity determining regions). The antigen-binding site is formed by one or more CDRs, yet the FR regions provide the structural framework for the CDRs and, hence, play an important role in antigen binding. By altering one or more amino acid residues in a CDR or FR region, the skilled worker routinely can generate mutated or diversified antibody sequences.
  • As a matter of example, the skilled worker can use the sequences of the antibodies provided herein (e.g. of Table 1 and/or Table 2) to design peptide variants that are within the scope of the present invention.
  • Furthermore, variants may be obtained by using one antibody of this first aspect of the invention as starting point for optimization by diversifying one or more amino acid residues in the antibody, preferably amino acid residues in one or more CDRs, and by screening the resulting collection of antibody variants. Diversification can be done by synthesizing a collection of DNA molecules using trinucleotide mutagenesis (TRIM) technology (Virnekiis B. et al., Nucl. Acids Res. 1994, 22: 5600.). Antibodies include molecules with modifications/variations including but not limited to e.g. modifications leading to altered half-life (e.g. modification of the Fe part or attachment of further molecules such as PEG), altered binding affinity or altered ADCC or CDC activity.
  • Polypeptide variants may be made that conserve the overall molecular structure of an antibody peptide sequence described herein. Given the properties of the individual amino acids, some rational substitutions will be recognized by the skilled worker. Amino acid substitutions, “conservative substitutions,” may be made, for instance, on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
  • For example, (a) nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, praline, phenylalanine, tryptophane, and methionine; (b) polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; (c) positively charged (basic) amino acids include arginine, lysine, and histidine; and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Substitutions typically may be made within groups (a)-(d). In addition, glycine and praline may be substituted for one another based on their ability to disrupt a-helices. Similarly, certain amino acids, such as alanine, cysteine, leucine, methionine, glutamic acid, glutamine, histidine and lysine are more commonly found in a-helices, while valine, isoleucine, phenylalanine, tyrosine, tryptophan and threonine are more commonly found in p-pleated sheets. Glycine, serine, aspartic acid, asparagine, and proline are commonly found in turns. Some preferred substitutions may be made among the following groups: (i) S and T; (ii) P and G; and (iii) A, V, Land I. Given the known genetic code, and recombinant and synthetic DNA techniques, the skilled scientist readily can construct DNAs encoding the conservative amino acid variants.
  • The third to tenth preferred embodiments of the antibodies pursuant to the first aspect of the present invention may also comprise a variable heavy chain which is at least 83.3%, 85%, 90%, 92%, 95% sequence identical to the variable heavy chain as presented by SEQ ID NO: 15, or at least 82.5%, 85%, 90%, 92%, 95% sequence identical to the variable heavy chain as presented by SEQ ID NO: 20.
  • The third to tenth preferred embodiments of the antibodies pursuant to the first aspect of the present invention may also comprise a variable light chain which is at least 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 16, or at least 87%, 90%, 92%, 95% identical to the variable light chain as presented by SEQ ID NO: 17, or at least 80.5%, 85%, 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 18, or at least 77.7%, 80%, 85%, 90%, 92%, 95% sequence identical to the variable light chain as presented by SEQ ID NO: 19.
  • All of the preferred embodiments of the antibodies pursuant to the first aspect of the present invention combine a variable heavy chain sequence comprising sequences as represented by SEQ ID NO: 5 (H-CDR 1), SEQ ID NO: 6 (H-CDR 2) and SEQ ID NO: 7 (H-CDR 3) with a variable light chain sequence comprising sequences as represented by SEQ ID NO: 8 (L-CDR 1), SEQ ID NO: 9 (L-CDR 2), SEQ ID NO: 10 (L-CDR 3).
  • The antibodies pursuant to the first aspect of the invention are preferably an IgG of any isotype (e.g., IgG1 IgG2, IgG3, IgG4). Their respective antigen-binding fragments may be a Fab, Fab′, F(ab′)2 or scFv, for example.
  • More preferably, the antibodies pursuant to the first aspect of the present invention are expressed as IgG1 isotype antibodies and are even more preferably humanized.
  • The most preferred antibodies of the first aspect of the present invention are those of the second, third and seventh embodiment (“HC0-LC0”, “HC6-LC6” and “HC7-LC6”), wherein amongst those the foremost preferred antibodies are those of the third and seventh embodiment (“HC6-LC6” and “HC7-LC6”).
  • All of the aforesaid preferred embodiments of the first aspect of the present invention are particularly advantageous, as they have been shown to display a very high affinity in the range of KD˜10−10 M, resulting in beneficial aspect of the present invention that they specifically, selectively and non-cross-reactive with other tissues of the CLL patient bind to the IGLV3-21R110-harboring BCR and thereby enable selective killing of malignant B-cells.
  • Regarding the most preferred antibodies (“HC0-LC0”, “HC6-LC6” and “HC7-LC6”), those display the highest affinity of only about between 1.2 to 2.1 10−10 M. The antibodies “HC6-LC6” and “HC7-LC6” according to the third and seventh preferred embodiment are additionally humanized, rendering them particularly suitable for therapeutic use due to their reduced immunogenicity.
  • All of the aforementioned embodiments of the first aspect of the invention selectively bind to IGLV3-21R110. Beyond the definition provided for IGLV3-21R110 above, said IGLV3-21R110 is in a generally preferred embodiment of this first aspect of the invention further characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein at position 16 of said sequence there is lysine and at positions 50 and 52 there are aspartates. In a generally more preferred embodiment of this first aspect of the invention, at position 49 there is a tyrosine or a phenylalanine and at position 51 there is a serine or a threonine. In a generally further more preferred embodiment of this first aspect of the invention at position 49 there is a tyrosine and at position 51 there is a serine.
    • Second Aspect of the Invention—Therapeutic Use
  • The second aspect of the present invention, pertains to the provision of the antibodies of the first aspect of the present invention for use in the treatment of CLL in IGLV3-21R110 positive patients. Likewise this second aspect of the present invention pertains to a method of treatment of CLL in IGLV3-21R110 positive patients, by administering a therapeutically active amount of antibodies of the first aspect of the present invention.
  • In a first preferred embodiment of this second aspect of the present invention, the antibodies are therefore characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
  • In a second preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a heavy chain corresponding to SEQ ID NO: 11 and a light chain corresponding to SEQ ID NO: 12.
  • In a third preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 16.
  • Within said third preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14 are more preferred.
  • In a fourth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 17.
  • Within said fourth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 22 are more preferred.
  • In a fifth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 18.
  • Within said fifth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 23 are more preferred.
  • In a sixth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 15 and a variable light chain region corresponding to SEQ ID NO: 19.
  • Within said sixth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 24 are more preferred.
  • In a seventh preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 16.
  • Within said seventh preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14 are more preferred.
  • In an eighth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 17.
  • Within said eighth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 22 are more preferred.
  • In a ninth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 18.
  • Within said ninth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 23 are more preferred.
  • In a tenth preferred embodiment of this second aspect of the present invention, the antibodies are characterized by a variable heavy chain region corresponding to SEQ ID NO: 20 and a variable light chain region corresponding to SEQ ID NO: 19.
  • Within said tenth preferred embodiment, antibodies characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 24 are more preferred.
  • As mentioned in the context of the first aspect of the present invention, all of the above referred to embodiments of the second aspect of the invention rely on antibodies that have a very high affinity. None thereof has an affinity of more than about 3·10−10 M at a capture rate of about 0.3 nm. From that alone the second aspect of the present invention allows a highly selective treatment of CLL in patients that are IGLV3-21R110 positive.
  • It has now further been demonstrated that these antibodies (see FIG. 1 ) may selectively discriminate between the wild-type IGLV3-21G110 variant and the malignant IGLV3-21R110 variant and that treatment with these antibodies in a xenograft mouse model (see FIG. 5 and Example 9) results in significant depletion of human IGLV3-21R110-positive B-cells, resulting in amelioration of CLL.
  • It has therefore been surprisingly found that the antibodies for use in the treatment of CLL in IGLV3-21R110-positive patients is efficacious.
  • Furthermore it could be shown that antibodies used for such treatment do not display cross-reactivity to other tissues (see FIG. 4 , Example 8).
  • The determination of an effective dose of such antibodies is well within the capability of those skilled in the art. For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., neoplastic cells, or in animal models, usually mice, rabbits, dogs, pigs or monkeys. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • A therapeutically effective dose refers to that amount of an antibody that ameliorates the symptoms or condition to be treated. In the context of the present invention, such condition to be treated is a clinically manifest CLL, which is caused by aberrant proliferation of B-cells that have an autonomously active BCR. More specifically the second aspect of the present invention addresses a clinically manifest CLL which is characterized by an aberrant proliferation of B-cells that have an autonomously active BCR harboring IGLV3-21R110.
  • All of the aforementioned embodiments of the second aspect of the invention pertain to the treatment of CLL in patients that are IGLV3-21R110 positive. Beyond the definition provided for IGLV3-21R110 above, said IGLV3-21R110 is in a generally preferred embodiment of this second aspect of the invention further characterized by a sequence identity of more than 80% to the sequence as represented by SEQ ID NO 53, wherein at position 16 of said sequence there is lysine and at positions 50 and 52 there are aspartates. In a generally more preferred embodiment of this first aspect of the invention, at position 49 there is a tyrosine or a phenylalanine and at position 51 there is a serine or a threonine. In a generally further more preferred embodiment of this first aspect of the invention at position 49 there is a tyrosine and at position 51 there is a serine.
  • A therapeutically effective amount is therefore an amount of an antibody that is of sufficient quantity to deplete IGLV3-21R110-positive CLL cells in a treated area of a patient—either as a single dose or according to a multiple dose regimen, yet which amount is toxicologically tolerable.
  • In the second aspect of the invention antibodies for the use in the treatment of CLL in IGLV3-21R110 positive patients are preferred that are employed at a dose from 0.25 to 25 mg/kgbodyweight, more preferably from 1 to 20 mg/kgbodyweight, most preferably from more than 7 to 15 mg/kgbodyweight and especially preferable from 8 to 12 mg/kgbodyweight.
  • These dosages are extremely low, resulting in an overall drug amount to be hypothetically administered to an average human patient of about 80 kg of no more than especially preferable between 640 to 960 mg to achieve strong depletion of malignant B-cells.
  • The exact dosage is chosen by the individual physician in view of the patient to be treated. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to achieve the desired effect. It has however been shown by the present invention that a twice weekly dosage of no more than 0.3 mg/kg is already efficacious in a xenograft mouse model, while strong depletion of malignant cells could be achieved at a dosage of 10 mg/kg (twice weekly).
  • When dosing the antibodies pursuant to the second aspect of the present invention, additional factors may also be taken into account, which may include the severity of the disease state, e.g., tumor size and location; age, weight and gender of the patient and diet. Further influencing factors to determine an adequate dose may be drug combination(s), reaction sensitivities, and tolerance/response to therapy.
  • Furthermore, the dosing may be performed more than once and time and frequency of administration may further influence the individual dosage administered.
  • Pursuant to the second aspect of the present invention, the antibodies may also be co-administered with known medicaments. Therefore they may be administered as the sole pharmaceutical agent or in combination with one or more additional therapeutic agents where the combination causes no unacceptable adverse effects. This combination therapy includes administration of a single pharmaceutical dosage formulation which contains antibodies pursuant to the first aspect of the invention and one or more additional therapeutic agents, as well as administration of an antibody of the first aspect of the invention and each additional therapeutic agent in its own separate pharmaceutical dosage formulation.
  • Where separate dosage formulations are used, treatment pursuant to the second aspect of this invention with one or more additional therapeutic agents may be at essentially the same time (e.g., concurrently) or at separately staggered times (e.g., sequentially). In particular, the treatment pursuant to the present invention may be performed in fixed or separate combination with other anti-tumor agents such as alkylating agents, anti-metabolites, plant-derived anti-tumor agents, hormonal therapy agents, topoisomerase inhibitors, camptothecin derivatives, kinase inhibitors, targeted drugs, antibodies, interferons and/or biological response modifiers, antiangiogenic compounds, and other anti-tumor drugs.
  • The antibodies of the present invention may also be employed in cancer treatment in conjunction with radiation therapy and/or surgical intervention.
    • Third Aspect—Polynucleotides
  • The present invention also relates to the DNA molecules that encode an antibody of the first aspect of the invention.
  • DNA molecules of the invention are not limited to the sequences disclosed herein, but also include variants thereof. DNA variants within the invention may be described by reference to their physical properties in hybridization. The skilled worker will recognize that DNA can be used to identify its complement and, since DNA is double stranded, its equivalent or homolog, using nucleic acid hybridization techniques. It also will be recognized that hybridization can occur with less than 100% complementarity. However, given appropriate choice of conditions, hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe. For guidance regarding such conditions see, Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA and Ausubel et al., 1995 (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Sedman, J. G., Smith, J. A., & S1ruhl, K. eds. (1995). Current Protocols in Molecular Biology. New York: John Wiley and Sons).
  • Structural similarity between two polynucleotide sequences can be expressed as a function of “stringency” of the conditions under which the two sequences will hybridize with one another. As used herein, the term “stringency” refers to the extent that the conditions disfavor hybridization. Stringent conditions strongly disfavor hybridization, and only the most structurally related molecules will hybridize to one another under such conditions. Conversely, non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness. Hybridization stringency, therefore, directly correlates with the structural relationships of two nucleic acid sequences. The following relationships are useful in correlating hybridization and relatedness (where Tm is the melting temperature of a nucleic acid duplex):
      • a. Tm=69.3+0.41(G+C) %
      • b. The Tm of a duplex DNA decreases by 1° C. with every increase of 1% in the number of mismatched base pairs.
      • c. (Tm)μ2−(Tm)μ1=18.5 log10μ2/μ1
        • where μ1 and μ2 are the ionic strengths of two solutions.
  • Hybridization stringency is a function of many factors, including overall DNA concentration, ionic strength, temperature, probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations, high ionic strengths, low temperatures, longer probe size and the absence of agents that disrupt hydrogen bonding. Hybridization typically is performed in two phases: the “binding” phase and the “washing” phase.
  • Yet another class of DNA variants within the scope of the invention may be described with reference to the product they encode. These functionally equivalent polynucleotides are characterized by the fact that they encode the same peptide sequences found in SEQ ID NOS: 1 to 24 due to the degeneracy of the genetic code.
  • It is recognized that variants of DNA molecules provided herein can be constructed in several different ways. For example, they may be constructed as completely synthetic DNAs. Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available. See Ausubel et al., section 2.11, Supplement 21 (1993). Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana et al., J. Mol. Biol. 72:209-217 (1971); see also Ausubel et al., supra, Section 8.2. Synthetic DNAs preferably are designed with convenient restriction sites engineered at the 5′ and 3′ ends of the gene to facilitate cloning into an appropriate vector.
  • As indicated, a method of generating variants is to start with one of the DNAs disclosed herein and then to conduct site-directed mutagenesis. See Ausubel et al., supra, chapter 8, Supplement 37 (1997). In a typical method, a target DNA is cloned into a single-stranded DNA bacteriophage vehicle. Single-stranded DNA is isolated and hybridized with an oligonucleotide containing the desired nucleotide alteration(s). The complementary strand is synthesized and the double stranded phage is introduced into a host. Some of the resulting progeny will contain the desired mutant, which can be confirmed using DNA sequencing. In addition, various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants.
  • As with the first aspect of the present invention, there are also corresponding preferred embodiments of this third aspect of the invention.
  • In a first preferred embodiment of this third aspect of the present invention, this invention pertains to DNA molecules encoding a heavy chain of one the preferred antibodies of the first aspect of the present invention as represented by any sequence selected from the list consisting of SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 33 and SEQ ID NO: 38.
  • In a second preferred embodiment of this third aspect of the present invention, this invention pertains to DNA molecules encoding a light chain of one the preferred antibodies of the first aspect of the present invention as represented by any sequence selected from the list consisting of SEQ ID NO: 26, SEQ ID NO: 30, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36 and SEQ ID NO: 37.
  • Nucleic acids of the invention are suitable for recombinant production of antibodies using standard vectors and host cells containing a nucleic acid sequence of the invention.
    • Further Aspects of the Invention
  • The antibodies of the first aspect of the present invention that are used in the second aspect of the present invention may be co-administered with known medicaments. For example, the antibody might be co-administered with any general anti-B-cell antibodies.
  • The present invention also relates to compositions comprising the antibodies according to any of the embodiments of the first aspect of the invention, which may be used analogously to the second aspect of the invention.
  • The invention, therefore, includes a pharmaceutical composition comprising an antibody pursuant to the first aspect of the invention alone or in combination with at least one other agent and a pharmaceutically acceptable carrier or excipient.
  • The other agent may be for instance a stabilizing compound and such at least one other agent and the antibody according to the first aspect of the invention may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water.
  • The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • A preferred pharmaceutical composition is made up from a lyophilized powder of the antibody according to the first aspect of the invention in 1 mM-50 mM histidine, 0.1%-2% sucrose, 2%-7% mannitol at a pH range of 4.5 to 5.5 that is combined with buffer prior to use.
  • After pharmaceutical compositions comprising an antibody of the invention formulated in an acceptable carrier have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition.
  • Consequentially, in a related aspect, the present invention also relates to such pharmaceutical compositions for use of CLL in IGLV3-21R110 positive patients. Likewise this related aspect of the present invention pertains to a method of treatment of CLL in IGLV3-21R110 positive patients, by administering a therapeutically active amount of said such pharmaceutical compositions.
  • Such administration is usually accomplished parenterally. Methods of parenteral delivery include topical, intra-arterial (directly to the tumor), intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, or intranasal administration.
  • The preferred routes of administration are intravenous and intra-arterial (directly to the tumor).
  • Pharmaceutical compositions for parenteral administration include aqueous solutions of active compounds. For injection, the pharmaceutical compositions of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances that increase viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
  • The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.
  • In another embodiment, the kits may contain DNA sequences encoding the antibodies pursuant to the third aspect of the invention. Preferably the DNA sequences encoding these antibodies are provided in a plasmid suitable for transfection into and expression by a host cell. The plasmid may contain a promoter (often an inducible promoter) to regulate expression of the DNA in the host cell. The plasmid may also contain appropriate restriction sites to facilitate the insertion of other DNA sequences into the plasmid to produce various antibodies. The plasmid may also contain numerous other elements to facilitate cloning and expression of the encoded proteins. Such elements are well known to those of skill in the art and include, for example, selectable markers, initiation codons, termination codons, and the like.
  • The invention therefore further relates to the aforementioned packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention for use in the treatment of CLL in IGLV3-21R110 positive patients.
  • A preferred embodiment of the invention is:
      • A. Antibodies for use in the treatment of CLL in IGLV3-21R110 positive patients, wherein said antibodies have
        • a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2; or
        • a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or
        • comprise a
        • variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 in any combination with a
        • variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
      • B. Antibodies for use according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
      • C. Antibodies for use according to embodiment A, characterized by a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12.
      • D. Antibodies for use according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14.
      • E. Antibodies for use according to embodiment A, characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14.
      • F. Antibodies for use according to embodiment A or C, which are chimeric.
      • G. Antibodies for use according to embodiment D and E, which are humanized.
      • H. Antibodies for use according to any of the preceding embodiments, wherein the antibodies are applied at a dose of from 0.25 to 25 mg/kgbodyweight.
      • I. Antibodies for use according to embodiment H, wherein the antibodies are applied at a dose of from 1 to 20 mg/kgbodyweight.
      • J. Antibodies for use according to embodiment H, the antibodies are applied at a dose of from 7 to 15 mg/kgbodyweight.
      • K. Antibodies for use according to embodiment H, the antibodies are applied at a dose of from 8 to 12 mg/kgbodyweight.
      • L. A pharmaceutical composition comprising an antibody according to any of the forgoing embodiments A to G alone or in combination with at least one other agent and a pharmaceutically acceptable carrier or excipient, for use in the treatment of CLL in IGLV3-21R110 positive patients.
      • M. A kit comprising a pharmaceutical composition according to embodiment L, for use in the treatment of CLL in IGLV3-21R110 positive patients.
    DESCRIPTION OF THE FIGURES
  • FIGS. 1A to 1D show FACS FSC-SSC plots (FIGS. 1A, 1C), as well as the gated plots of mAb01-01-APC (FIGS. 1B, 1D, x-axis) over anti-IgM-PE (FIGS. 1B, 1D, y-axis).
  • Pursuant to Example 4 the plots in FIGS. 1A and 1B were made from a 1:1 cell mix comprising IGHV3-21/IGLV3-21R110 BCR positive TKO mouse cells and TKO cells lacking a BCR (cell mix A) stained with the above fluorescence labelled antibodies, while the plots in FIGS. 1C and 1D were made from a 1:1 cell mix comprising IGHV3-21/IGLV3-21G110 BCR positive TKO mouse cells and TKO cells lacking a BCR (cell mix B).
  • As can be readily appreciated from FIGS. 1B and 1D, nearly the half of the analysed TKO cells are positively stained with the respective anti-IgM antibodies, indicating that they possess a BCR, which is consistent with the expression of the BCR on the surface of approximately 50% of the TKO cells of the respective cell mixes. By virtue of comparison of FIGS. 1B and 1D, it becomes apparent that the antibody of the present invention “mAb01-01” only recognizes the malignant variant of IGLV3-21 bearing the R110 mutation.
  • FIGS. 2A to 2F show FACS plots of human PBMC's processed pursuant to Example 6. FIGS. 2A and 2D show FSC-SSC representations of said PBMC's in which a gate has been set likewise to FIGS. 1A and 1C to apparently living cells. The gated cells are plotted to have anti-CD19-VioBright515 over anti-CD5-PE-Cγ5 (FIGS. 2B and 2E) as well as anti-CD19-VioBright515 over mAb01-01-APC (FIGS. 2C and 2F). FIGS. 2A to 2C depict an analysis of human PBMC's of a patient that was positively diagnosed of having B-cells expressing an IGHV4-39/IGLV3-21R110-BCR and FIGS. 2D to 2F depict the same analysis of human PBMC's of a patient whose CLL is not characterized by a IGHV3-21R110-BCR (i.e. non-IGLV3-21R110 CLL). As can be seen from the comparison of FIGS. 2B and 2D, CD5/CD19++ B-cells could be resolved and further comparison between the two patients samples (FIGS. 2C and 2F) shows that mAb01-01 selectively identified IGLV3-21R110-positive CLL B-cells only, allowing the differentiation between CLL types.
  • FIG. 3 shows a comparative binding kinetic of the antibodies HC0-LC0, HC6-LC6 and HC7-LC6 pursuant to the present invention and in accordance with Example 7. As can be seen, these three antibodies display essentially the same binding kinetic and have a near to identical binding specificity latest at 10 μg/ml concentration.
  • FIG. 4 shows a comparison of (left column) tissues stained with mAb01-01 and an anti-IgG against such mAb01-01 (sandwich-assay) against sole treatment of the same tissue samples solely with anti-IgG (right column) pursuant to Example 8. The top row shows the respective result in a tissue sample of a CLL patient that is IGLV3-21R110-positive, while the lower rows show results in healthy donor samples.
  • From the comparison of the top left picture to all of the remainder pictures of the left column can be seen that the mAb01-01 positively and selectively identifies diseased B-cells in the spleen of a diseased patient and that there is no cross-reactivity to any of the healthy donor's samples neither in the same tissue (spleen), nor in any of the other tissue types (skin, kidney, heart and brain). This shows that the antibodies of the present invention are selective, safe and non-cross-reactive. The further pictures of the right column show that the staining achieved in the top left picture and also the lack of staining in lower pictures of the left column is not related to any background or other artificial effect.
  • FIG. 5 shows the absolute number of CLL cells in the spleen upon termination of the experiment pursuant to Example 9. In said experiment a xenograft mouse model, artificially suffering from IGLV3-21R110-positive CLL was treated with a (pharmaceutically inactive) control (Group A), an amount of 0.3 mg/kg (Group B), an amount of 5 mg/kg (Group C) and 10 mg/kg (Group D) bodyweight of mAb01-01. As can be seen from this figure, all treatments result in a depletion of CLL-cells in the spleen, while at 10 mg/kg the depletion is extraordinary significant. This shows that the antibodies of the present invention indeed facilitate an efficacious treatment of CLL characterized by IGLV3-21R110-positive BCRs.
  • FIG. 6 shows a schematic representation of BCR-BCR homotypic interaction of IGLV3-21R110 light chains (as described by Minici et al.). Two neighbouring BCRs are depicted with antigen-binding subunit comprising heavy (HC) and light chains (LC), transmembrane domain (TM), well as the signaling subunit (SU) composed of disulfide-linked heterodimer of the Igα and Igβ proteins (CD79a/CD79b). Mutated arginine at position 110 (R) of one BCR interacts with a germline-encoded aspartate (D) at position 50 of an adjacent BCR. A further interaction between the two BCRs is mediated by the germline-encoded amino acid residues lysine (K) at position 16 and aspartate (D) at position 52.
  • FIG. 7 shows schematic representations of IGLV3-21R110. FIG. 7A: exemplarily IGLV3-21R110 (SEQ ID NO: 53) in one-letter code. Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al. are marked in bold. FIG. 7B: Line 1: Amino acid position in IGLV3-21R110. Line 2: Amino acid residues involved in BCR-BCR homotypic interactions according to Minici et al. Lines 3 to 5: Different variants of the YDSD-motif in comparison. Amino acids are depicted in 3-letter code.
  • FIG. 8 shows the sequences according to SEQ ID NOs: 1 to 53. SEQ ID NOs: 1-10 show various sequences from the organism Mus musculus. SEQ ID NOs: 11-48 show various synthetic construct sequences. SEQ ID NOs: 49-53 show various sequences from the organism Homo sapiens.
  • The present invention is further described by the following examples. The examples are provided solely to illustrate the invention by reference to specific embodiments. These exemplifications, while illustrating certain specific aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.
  • All examples were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following examples can be carried out as de-scribed in standard laboratory manuals, such as Sambrook et al., 1989 supra.
  • A preferred embodiment of the invention is:
    • EXAMPLES Example 1 Generation of Murine Antibodies Immunization and Generation of Hybridoma Cell Line
  • A murine antibody to the IGLV3-21R110-harboring BCR was developed by a combination of immunization of mice with a soluble form of the BCR and selection of suitable antibodies using a cell system in which the complete and functional BCR was presented membrane bound.
  • At first, a soluble form of the BCR in the form of an IgG1 had to be obtained for immunization of mice. Therefore, a DNA segment encoding IGHV3-21 as an exemplary variable heavy chain (VH) and a complete light chain (LC) DNA covering IGLV3-21R110 were synthesized by a contract manufacturer using a standard procedure. These were then fused with a murine IgG1 constant segment by polymerase chain reaction (PCR) and cloned into a cytomegalovirus (CMV) vector. A human cellular expression system based on HEK293T cells was used for the expression of such IgG1 (SEQ ID NO: 49 for VH, and SEQ ID NO: 50 for LC) as previously described, e.g. in Rekombinante Antikörper, Lehrbuch und Kompendium für Studium und Praxis, 2. Auflage, Springer Verlag 2019. A polyethyleneimine (PEI) based protocol was used for transfection. After several passages, the supernatant was pooled and the medium contained in the combined cell supernatant was purified using Protein G columns. The purity and quality of the soluble IgG1 was determined by Western blotting.
  • Thereafter, mice were immunized with the recombinantly produced soluble form of the BCR (cf. SEQ ID NOS: 49 and 50).
  • Immune cells with the desired specificity could then be obtained from these mice and transformed into hybridoma cells by cell fusion. Second, FACS screening methods were performed with triple knockout cells (TKO; knockout for the genes Lambda5, RAG2 and SLP65) expressing various variants for the BCR to select for antibodies specifically targeting BCRs harboring IGLV3-21R110.
  • Monoclonal antibody was produced using the standard procedure in mice and the subsequent generation of hybridoma cells.
  • This approach allowed the isolation of the unique monoclonal antibody “mAb01-01” (SEQ ID NO: 1 for heavy chain, and SEQ ID NO: 2 for light chain).
    • Selection of Monoclonal Antibody
  • The screening for positive clones was not performed by enzyme linked immunosorbent assay (ELISA) as usual. Since the target structure is a membrane-bound receptor, it is of central importance to validate the binding of the potential antibodies in a cellular system, i.e. while largely preserving the cell physiological states native to this cell type. First, groups of pooled supernatants were examined for binding events using fluorescence activated cell sorting (FACS) analysis. For this purpose different BCR variants were expressed on the surface of a triple knockout (TKO) cell line, which cannot express BCR itself.
  • The starting point for the production of TKO cells is formed by transgenic mice which have a respective knockout for the genes Lambda5, RAG1 or RAG2 and SLP65 (Dühren von Minden et al., 2012, Nature 489, p. 309-313). The combination of the knockouts of RAG2 or RAG1 and Lambda5 leads to a blockade in the transition from the pro-B cell stage to the pre-B cell stage, which is classically characterized by the beginning rearrangement of the VDJ segments of the heavy chain (HC). Therefore they are pro-/pre-B cells. The activity of the BCR can be measured by reconstitution with the inducible SLP65. The production of such mice is known to the expert and belongs to the state of the art. To obtain the cells, the bone marrow of the femur was extracted from the mice after they had been sacrificed. The cells obtained in this way were then cultured under conditions that promote the survival of pro-/pre-B cells (37° C., 7.5% CO2, Iscoves medium, 10% FCS, P/S, murine IL7). After several passages, FACS sorting was carried out for control purposes, the pro-/pre-B cells were sorted and then returned to culture. The markers used for this purpose are known to the specialist.
  • For reconstitution with a ‘BCR of interest’, the corresponding sequence coding for the VH was fused with a human IgM constant segment by polymerase chain reaction (PCR), and heavy (HC) and light (LC) chains were cloned into respective expression vectors each having a CMV promoter. These were introduced into the packaging cell line (Phoenix cell line) by lipofection. After 36 hours of incubation, the virus supernatant was removed and used for Spinfektion of the TKO cells. BCR expression was determined using anti-IgM and anti-LC antibodies on FACS. For this purpose, some cells were taken and stained with 5 μl antibody each in a total volume of 100 μl in PBS. Both the work to extract the supernatants and the Spinfektion of the TKO are widely known procedures and known to experts. Knockout of RAG2 or RAG1 and Lambda5 ensured that only the “BCR of Interest” was expressed on the surface.
  • In this way, two different BCR-expressing TKO cell lines were generated, one of which expressed the membrane-bound IGHV3-21/IGLV3-21R110 BCR. For the generation of the second BCR-expressing TKO cell line, the codon for the arginine at position 110 of the DNA encoding IGLV3-21R110 was reverted to the germline sequence by well-known site-directed mutagenesis technique (see, e.g. Sambrook et al., 1989 supra). The resulting TKO cells expressed a BCR containing IGLV3-21 with glycine at amino acid position 110 (IGLV3-21G110). To generate a third control TKO cell line without BCR expression on its surface, spinfection with an empty expression vector was performed. By using an inducible SLP65 to reconstitute the cells, the function of the expressed BCRs could be characterized and the autonomously active state of the IGHV3-21/IGLV3-21R110 BCR on the surface could thus be verified before selection. The method of choice here is the measurement of Ca-flux after induction of SLP65 using FACS analysis and the use of a Ca2+ dependent dye such as Indo-1. These methods are known to the expert (see M. Dühren-von Minden et. al; Nature 2012). With these cells as “targets”, FACS has now been used to identify an antibody that specifically binds to IGLV3-21R110-harboring BCRs. The first step was to identify the supernatants whose antibodies showed a binding. In this 1st selection round, supernatants of several clones were combined and examined with regard to their binding profile. A positive binding profile is given if a specific binding to the IGHV3-21/IGLV3-21R110-BCR is shown. Groups showing such a profile were isolated, and the binding profile of the individual clones was characterized again during a second selection round. Binding of the monoclonal antibodies was verified using a FACS binding assay using a fluorescently labeled anti-mouse IgG antibody.
  • This selection approach led to the identification of the antibody mAb01-01, which binds the IGHV3-21/IGLV3-21R110 BCR positive TKO mouse cells, but not IGHV3-21/IGLV3-21G110 BCR positive TKO mouse cells.
    • Production of Murine Antibody
  • After identification of a preferred antibody by selection, mRNA was isolated from the individual hybridoma clone, cDNA was generated and amplified by Anchor PCR (Rapid expression cloning of human immunoglobulin Fab fragments for the analysis of antigen specificity of B cell lymphomas and anti-idiotype lymphoma vaccination; Osterroth F, Alkan O, Mackensen A, Lindemann A, Fisch P, Skerra A, Veelken H. J Immunol Methods 1999 Oct. 29; 229(1-2):141-53). The sequence of the cDNA encoding the monoclonal antibody mAb01-01 was confirmed by Sanger sequencing (SEQ ID NO: 25 for HC nucleotide, SEQ ID NO: 26 for LC nucleotide) and placed into a vector suitable for expression in CHO cells.
  • Expression of the mAb01-01 as IgG1 subtype was verified using secondary anti-murine IgG1-APC and IgG2-APC antibodies. For this purpose, IGHV3-21/IGLV3-21R110-expressing TKO cells were stained in one batch with the secondary antibody alone and in another batch with mAb01-01 and the secondary antibody. Subsequent FACS analysis confirmed that the antibody had been expressed as IgG1.
  • The specific monoclonal antibody mAb01-01 was sequenced. The following amino acid sequences were determined as depicted in Table 1: SEQ ID NO: 1 for the HC, SEQ ID NO: 2 for the LC, SEQ ID NO: 3 for the VH, SEQ ID NO: 4 for the VL. The sequences corresponding to complementarity determining regions (CDR) of the heavy chain, H-CDR1, H-CDR2 and H-CDR3 are included in SEQ ID NOS: 5, 6 and 7, while the sequences corresponding to the light chain CDRs, L-CDR1, L-CDR2 and L-CDR3 are included in SEQ ID NOS: 8, 9 and 10.
    • Example 2 Generation of Chimeric Antibodies
  • Using the murine monoclonal antibody mAb01-01 VH and VL nucleotide sequences (SEQ ID NO: 27 for VH Nucleotide, and SEQ ID NO: 28 for VL Nucleotide) a chimeric antibody was synthesized. For this purpose, the VH sequence was fused with a human IgG1 isotype constant domain sequence (SEQ ID NO: 31 for IgG1 constant Nucleotide) and the VL sequence was fused with a human Igκ isotype constant domain (SEQ ID NO: 32 for Igκ constant Nucleotide) by PCR and expressed using a CHO based transient expression system. The resulting antibody containing cell culture supernatant was clarified by centrifugation and filtration. The chimeric antibody was purified from cell culture supernatant via affinity chromatography. The purity of the antibody was determined to be >95%, as judged by reducing and denaturing Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). The antibody was analyzed for protein content and concentration via Seize Exclusion Chromatography (SEC) in PBS-buffer. All steps were performed with state-of the-art equipment and techniques.
  • This approach resulted in the chimeric antibody “HC0-LC0”, the sequences of which are summarized in Table 1.
  • TABLE 1
    Sequences of murine and chimeric antibodies
    SEQ SEQ SEQ SEQ SEQ SEQ SEQ ID SEQ ID
    Anti- ID NO: ID NO: ID NO: ID NO: ID NO: ID NO: NO: VH NO: VL
    body HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 Protein Protein
    mAb01-01 5 6 7 8 9 10 3 4
    HC0-LC0 5 6 7 8 9 10 3 4
    SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID
    SEQ ID SEQ ID NO: VH NO: VL NO: HC NO: LC NO:
    Anti- NO: HC NO: LC Nucle- Nucle- Nucle- Nucle- HC + LC
    body Protein Protein otide otide otide otide Protein
    mAb01-01 1 2 27 28 25 26 39
    HC0-LC0 11 12 27 28 29 30 40
    • Example 3 Generation of Humanized Antibodies
  • Humanization of mAb01-01 was carried out by in silico grafting the murine CDR's into mature human antibody frameworks using standard CDR-grafting technologies by Fusion Antibodies Plc, Belfast, N. Ireland. Key residues important for the VH/VL interface and canonical loop structure have been maintained as much as possible in the humanized variants using the CDRx platform (Fusion Antibodies Plc, Belfast, N. Ireland). Subsequently, the amino acid sequences of the humanized variants generated by fusion antibodies were converted to nucleotide sequences using Geneiouse software (Geneious Prime 2, Auckland, New Zealand). By fusing VH sequences with a human IgG1 isotype constant domain sequence (SEQ ID NO: 31 for IgG1 constant Nucleotide) and VL sequences with a human Igκ isotype constant domain (SEQ ID NO: 32 for Igκ constant Nucleotide) by PCR, 16 pairs of the humanized heavy and light chains were generated, and the antibody gene sequences expressed transiently in Chinese Hamster ovary cells (CHO). Following batch culture, expressed humanized antibodies were purified from the cell culture supernatant and analyzed as described in Example 2 for HC0-LC0. Eight humanized antibodies as depicted in Table 2 were successfully yielded.
  • TABLE 2
    Sequences of humanized antibodies
    SEQ SEQ SEQ SEQ SEQ SEQ SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID NO:
    ID NO: ID NO: ID NO: ID NO: ID NO: ID NO: NO: VH NO: VL NO: HC NO: LC NO: VH NO: VL HC + LC
    Antibody HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 Protein Protein Protein Protein Nucleotide Nucleotide Protein
    HC6- 5 6 7 8 9 10 15 16 13 14 33 34 41
    LC6
    HC6- 5 6 7 8 9 10 15 17 13 22 33 35 42
    LC7
    HC6- 5 6 7 8 9 10 15 18 13 23 33 36 43
    LC8
    HC6- 5 6 7 8 9 10 15 19 13 24 33 37 44
    LC9
    HC7- 5 6 7 8 9 10 20 16 21 14 38 34 45
    LC6
    HC7- 5 6 7 8 9 10 20 17 21 22 38 35 46
    LC7
    HC7- 5 6 7 8 9 10 20 18 21 23 38 36 47
    LC8
    HC7- 5 6 7 8 9 10 20 19 21 24 38 37 48
    LC9
    • Example 4
  • Binding of mAb01-01 to IGLV3-21R110-BCR and IGLV3-21G110-BCR Expressing TKO Cells
  • The specificity of the antibody mAb01-01 observed in the selection (Example 1) was verified in a FAGS assay using the antibody coupled to a fluorescent marker.
  • For this purpose, from the three different TKO cell lines according to Example 1 two cell mixtures, cell mix A and cell mix B, were prepared and subsequently stained with mAb01-01-APC (mAb01-01 was coupled with fluorescent marker APC by Immunotools GmbH). For control, each batch was additionally stained with anti-IgM antibody (Anti-human IgM-PE, Clone: MHM-88, BioLegend Cat-No.: 314508).
  • Cell mix A was prepared at a 1:1 ratio of IGHV3-21/IGLV3-21R110 B-cell receptor expressing TKO cells and B-cell receptor negative (empty vector; control) TKO cells in PBS buffer (Gibco, pH 7.2, Cat. no. 20012-019).
  • Cell mix B was prepared at a 1:1 ratio of IGHV3-21/IGLV3-21G110 B-cell receptor expressing TKO cells and B-cell receptor negative (empty vector; control) TKO cells in PBS buffer.
  • Cells of cell mix A or B were suspended at approximately 106 cells per FACS tube in dilutions of the antibodies (5 μg/ml mAb01-01-APC, 2 μg/ml Anti-human IgM-PE, in a total volume of 100 μl) in PBS buffer, and incubated for 15 min at 4° C. in the dark. In the following, cells were washed once with 1 ml cold PBS buffer, resuspended in 200 μL cold PBS buffer.
  • FACS analysis was performed by using a MACSQuant Analyzer 10 (Miltenyi Biotec B.V. & Co. KG; the instrument was calibrated as recommended by the manufacturer, flow rate: Low, Mix sample: Mix gentle, Mode, Standard, Uptake volume: 50 μL, Sample volume: 200 μL). TKO-cells of cell mix A or cell mix B were gated in a side scatter (SSC) vs. forward scatter (FSC) and the gated TKO-cells were analysed in anti-IgM-PE vs. mAb01-01-APC dot-plot to enumerate the different TKO-cell populations using quadrant stats.
  • As shown in FIGS. 1A to 1D, mAb01-01 binds to murine TKO cells expressing human IGLV3-21R110-BCR, whereas no binding occurs to human IGLV3-21G110-BCR expressing TKO mouse cells.
    • Example 5 Affinity of Antibodies for the IGLV3-21R110 B-Cell Receptor
  • To define the binding affinities of the antibodies to the IGLV3-21R110-harboring B-cell receptor, a soluble recombinant version of the BCR (170.5 kDa; sequence according to SEQ ID NO: 51 for HC and 52 for LC) was produced in 293-HEK cell line as monomeric human IgM by transient expression using a protocol described in Example 1, and binding to immobilized anti-IGLV3-21R110 antibodies was monitored by Bio-Layer Interferometry (BLI) on a Fortebio Octet instrument (Satorius).
  • Kinetic assays were performed by first immobilizing the anti IGLV3-21R110 antibodies onto biosensors through an indirect capturing reagent, anti-human IgG Fc antibody. Anti IGLV3-21R110 antibodies were loaded at a concentration of 0.01875 μg/ml to generate an anti IGLV3-21R110 antibody capture level of between 0.30 and 0.34 nm. A 9 nM BCR-fragment solution in running buffer (PBS, 0.02% Tween20, 0.1% BSA, 0.05% sodium acide) was prepared and serial diluted 1:3 to obtain 7 concentrations from 9 to 0.012 nM (9 nM, 3 nM, 1 nM, 0.333 nM, 0.111 nM, 0.037 nM, and 0.012 nM). The anti IGLV3-21R110 antibody capture biosensors were then submerged in wells containing the different concentrations of the soluble BCR-fragment for 900 seconds (association stage) followed by a dissociation step of 1200 seconds in running buffer. Steps were performed at a constant shake speed of 1000 rpm. All reagents were used as described by the manufacturer. Sensorgrams were generated after double reference correction (buffer and blank sensors) to compensate for both the natural dissociation of the capture anti IGLV3-21R110 antibody and also non-specific binding of the soluble BCR-fragment to the sensor surface. Dissociation rate constants (KD) were calculated based on the ratio of association (ka) and dissociation rate (kd) constants, obtained by fitting sensorgrams with a first order 1:1 binding model using the Fortebio Data Analysis software (Satorius).
  • As shown in Table 3, chimeric antibody HC0-LC0 binds with a KD value around 120 nM the soluble IGLV3-21R110 B-cell receptor. The humanized antibodies HC6-LC6 and HC7-LC6 exhibit binding characteristics similar to that of chimeric antibody HC0-LC0, exhibiting dissociation constants within 2-fold of the chimeric antibody HC01 LC01. For the KD values of all humanized antibodies, see Table 3.
  • TABLE 3
    Monovalent KD values of chimeric antibody HC0-LC0 and humanized
    variants as measured by Fortebio with soluble IGLV3-21R110 B-cell
    receptor and anti IGLV3-21R110 antibody Capture levels
    Antibody KD (M) Capture level (nm)
    HC0-LC0 1.21E−10 0.322
    HC6-LC6 2.11E−10 0.305
    HC6-LC7 3.47E−10 0.337
    HC6-LC8 2.77E−10 0.313
    HC6-LC9 2.91E−10 0.311
    HC7-LC6 1.75E−10 0.322
    HC7-LC7 2.69E−10 0.323
    HC7-LC8 2.49E−10 0.330
    HC7-LC9 3.13E−10 0.280
    • Example 6
  • Binding of Murine Antibody mAb01-01 to Cell Surface of IGLV3-21R110-BCR Positive Human B-CLL Cells
  • To determine the binding characteristics of the mAb01-01 on IGLV3-21R110-B-cell receptor positive human CLL cells vs. non-IGLV3-21R110 human B-cells, binding was tested by flow cytometry.
  • For this purpose, cryopreserved peripheral blood mononuclear cells (PBMCs) of two CLL patients were used. The CLL in one of these patients was characterized by the presence of IGLV3-21R110. More specifically, the CLL cells expressed a BCR with a combination of IGLV3-21R110 with IGHV4-39 heavy chain (IGHV4-39/IGLV3-21R110-BCR). The other patient had been diagnosed suffering with a non-IGLV3-21R110 CLL. The PBMCs could be separated from heparinized venous blood by Ficoll-Paque PLUS (GE Healthcare Bio-Sciences AB) density gradient centrifugation using a technique that is known in the art, e.g. according to Bøyum A. Isolation of mononuclear cells and granulocytes from human blood. Scan. J. Clin. Lab. Invest. 1968, 21 (Suppl. 97): 77-89.
  • Samples where thawed and resuspended in 5 ml cell culture medium (RPMI, Gibco; 10% FCS, PAN-Biotec). Cells were centrifuged by 300 g (Eppendorf centrifuge 5425R), followed by additional resuspension in 1 ml RPMI. Cell count was acquired by using a Neubauer Chamber. For staining 1×10E6 cells were used and transferred in a FACS-tube. Cells were stained using 2 μl anti-CD19 VioBright515 (Miltiny Biotech, Klon:REA675,), 2 μl Anti-CD5-PE-Vio770 (Miltenyi Biotec, Klon:REA782), and 5 μl mAb01-01-APC (mAb01-01 was coupled with fluorescent markers APC by Immunotools GmbH) in a total volume of 100 μl PBS buffer, and incubated for 15 min at 4° C. in the dark. In the following, cells were washed once with 1 ml cold PBS buffer, resuspended in 200 μL cold PBS buffer and analysed by flow cytometry using a BD LSRFortessa™ Cell Analyzer (BDbioscience). The instrument was calibrated as recommended by the manufacturer. The Analysis of the raw data were performed by using the FlowJo-Software X (BDbioscience). The analysis gates where set as demonstrated in FIG. 2 .
  • As shown in FIG. 2 , the mAb01-01 binds exclusively to IGLV3-21R110 positive CLL B cells, but not to BCRs of a CLL patient, which does not harbor IGLV3-21R110. More specifically, mAb01-01 recognizes the IGLV3-21R110-BCR irrespective of the nature of the heavy chain.
    • Example 7 Binding Characteristics of Chimeric and Humanized Antibodies to Cell Surface of IGLV3-21R110-BCR Positive Murine TKO Cells
  • To compare the specific IGLV3-21R110-BCR binding of the chimeric antibody and two humanized versions, IGLV3-21R110-BCR murine TKO cells (see Example 1) were incubated with different concentrations of the antibodies HC0-LC0, HC6-LC6 and HC7-LC6 and analysed by flow cytometry and a sandwich assay setup. Controls were performed with a TKO—empty vector cell line (without surface BCR).
  • From each cell line, 7.5×10E6 cells are transferred into a separate 15 ml bluecap, centrifuged for 10 minutes (300 g, at 4° C.), and resuspended in 1.5 ml PBS (Gibco).
  • Staining where performed in a 96-well plate (VWR, U-bottom, non-treated). For each reaction 2×10E5 cells were used. The experimental setup is shown in Table 4.
  • TABLE 4
    Experimental setup of the 96-well plate
    well No./Conc. (μg/ml)
    1 2 3 4 5 6 7 8 9 10 1st Ab
    A: TKO-R110 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC0/LC0
    B: TKO-emty vector 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC0/LC0
    C: TKO-R110 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC7/LC6
    D: TKO-empty vector 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC7/LC6
    C: TKO-R110 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC6/LC6
    D: TKO-empty vector 10.00 5.00 2.50 1.25 0.63 0.31 0.16 0.08 0.04 0.00 HC6/LC6
  • To characterize the binding characteristics of the different humanized variants 10 different concentrations of each antibody in PBS were used for staining (10, 5, 2.5, 0.625, 0.31, 0.16, 0.08, 0.04, 0 μg/ml) in a total volume of 200 μl per well. Incubation was performed for 30 min at 4° C., dark. The 96-well was then centrifuged (VWR, MEGA STAR 1.6R) for 10 min at 300 g, 4° C. Supernatants were discarded and the cells were resuspended in 100 μl ice cold PBS. For detection a secondary antibody directed to human IgG1 labeled with APC was used in a final concentration of 10 μg/ml.
  • Incubation was performed in 200 μl/well total volume for 15 min at 4° C. in the dark, followed by an additional washing step with ice cold PBS. Cells were resuspended in 150 μl ice cold PBS for acquisition. Cells were analysed on a MACS-Quant10 (Miltenyi Biotec), calibrated followed by the instruction of the manufacturer.
  • MFI (median fluorescence intensity) of all IGLV3-21R110-BCR TKO measurements was neutralized by subtracting the control cell values and plotted against the concentration of the antibodies. Functions were generated demonstrating a concentration-dependent increase in binding of the IGLV3-21R110-BCR for all three antibodies. As shown in FIG. 3 , the two humanized variants exhibit increasingly identical binding properties to the chimeric antibody with increasing antibody concentration and have nearly identical binding specificities at 10 μg/ml at the latest.
    • Example 8
  • Tissue Cross-Reactivity Profile of mAb01-01 To determine the binding characteristics of mAB01-01 to human CLL and healthy tissue in immunohistochemistry (IHC) experiments, immunostaining was performed on sections of spleen tissue expressing the IGLV3-21R110-BCR and of healthy spleen, skin, kidney, heart, and brain tissue.
  • Prior to IHC, the tissue sections were deparaffinized and hydrated. To unmask the antigens, microwave treatment with citrate buffer pH 6.0 (9 ml citric acid (0.1M) and 41 ml sodium citrate (0.1 M)) was performed. For this, the sections were boiled in the bubbling citrate buffer for 15 min, after which they chilled at room temperature for 30 min and then they were rinsed in PBS 3×5 min. For IHC, the slides were incubated for 2 hr with the first antibody at a dilution of 1:200 at RT in a humidity chamber. As a control, sections of all tissues were incubated under identical conditions without the first antibody. Thereafter, the slides were washed in PBS 3×5 min. An anti-IgG antibody conjugated with horseradish peroxidase (HRP) (Goat Anti-Mouse IgG(H+L)-HRP, Southern Biotech, Cat. No. 1036-05) as a secondary antibody was incubated for 1 hour at a dilution of 1:10000 at RT in a humidified chamber. Subsequently, it was washed with PBS for 10 min and a DAB substrate kit (#34065, Thermo Fisher) was used to detect the activity of the HRP. DAB (3,3′-Diaminobenzidine tetrahydrochloride) substrate was incubated for 15 min. Fluoromount-1 was used as the capping agent. The evaluation was done after 30 minutes and showed an insoluble, brown colored reaction product at the sites where HRP conjugated anti-IgG antibody bound to the tissue.
  • As shown in FIG. 4 , positive staining could be observed for the IGLV3-21R110-BCR positive spleen section, thus mAb01-01 is cross-reactive in binding to human CLL-tissue. In contrast, no staining was detected in healthy human tissue sections of spleen, skin, kidney, heart, and brain. Thus mAB01-01 shows no cross-reactivity with healthy human tissue.
    • Example 9 Test of Anti-IGLV3-21R110-BCR Antibodies in a Patient Derived Xenograft Model
  • To determine the efficacy of the anti-IGLV3-21R110 antibodies a patient derived xenograft model was chosen. For a Dose finding experiment 4 groups with 4 NOD-scid IL2rg null (NSG)-mice (Jackson ImmunoResearch, prepared as described in Qi J et al.: An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies, Methods 2019, 154:70-76) were used:
      • Group A: control group without antibody treatment
      • Group B: dose 0.3 mg/kg body weight
      • Group C: dose 5 mg/kg body weight
      • Group D: dose 10 mg/kg body weight
  • PMBS from an IGLV3-21R110-BCR patient were thawed and resuspended in PBS. T cells where separated by using Miltenyi CD3 Beads (Miltenyi Biotec) following the instruction for use provided by the manufacturer. T cells were cultured and expanded for 7 days using CD3/CD28 dynabeads (Dynabeads™ Human T-Activator CD3/CD28 for T Cell Expansion and Activation, Cat. No. 11161D, GIBCO) as described before (Qi J et al. Methods, 2019 s.a.).
  • After 7 days, the activated T cells and PBMCs (20×106 CLL PBMCs and 5×105 T cells per mouse) were injected i.v. into NSG mice. For treatment mAb01-01 was given in different dosages i.p., twice a week for total 3 weeks, starting at week 2 post engraftment. Mice where pre-conditioned at the beginning of every week with 250 μl human serum. The mice were sacrificed after 3 weeks of treatment. For analysis the spleen was isolated and analyzed for the existence of human IGLV3-21R110 positive CLL B cells by flow cytometry using the mAb01-01 and antibodies against human CD45, CD5, and CD19 (CD5 IgG1 UCHT2, BioLegend; CD19 IgG1 HIB19, BD Biosciences; CD45 (human) IgG1 H130 Invitrogen). For flow cytometry, cells were collected by centrifugation and resuspended in ice-cold 0.1% (w/v) BSA in PBS (flow cytometrybuffer). 100 μL containing 5×105 cells were distributed into a V-bottom 96-well plate (Corning). The cells were first blocked with 5% (v/v) goat serum (Jackson ImmunoResearch) for 30 min on ice and then incubated with the indicated antibodies as recommended by the manufacturer. The cells were incubated for 30 min on ice in dark. Then the cells were washed twice with ice-cold flow cytometry buffer, resuspended in 200 μL flow cytometry buffer and analyzed using FACSCanto (BD Biosciences).
  • As shown in FIG. 5 , the treatment with mAb01-01 led to a reduction in tumor cell counts in all treated mice, and treatment with 10 mg/kg mAb01-01 reduced tumor growth supremely.

Claims (20)

1. A method of treatment of CLL in IGLV3-21R110 positive patients comprising administering antibodies, wherein said antibodies have
a heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2; or
a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12; or
comprise a
variable heavy chain having a sequence selected from the list consisting of SEQ ID NO: 15 and SEQ ID NO: 20 in any combination with a
variable light chain having a sequence selected from the list of SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, and SEQ ID NO: 19.
2. The method according to claim 1, wherein said antibodies are characterized by a heavy chain corresponding to SEQ ID NO: 1 and a light chain corresponding to SEQ ID NO: 2.
3. The method according to claim 1, wherein said antibodies are characterized by a heavy chain amino acid sequence of SEQ ID NO: 11 and a light chain amino acid sequence of SEQ ID NO: 12.
4. The method according to claim 1, wherein said antibodies are characterized by a heavy chain corresponding to SEQ ID NO: 13 and a light chain corresponding to SEQ ID NO: 14.
5. The method according to claim 1, wherein said antibodies are characterized by a heavy chain corresponding to SEQ ID NO: 21 and a light chain corresponding to SEQ ID NO: 14.
6. The method according to claim 1, wherein said antibodies are chimeric.
7. The method according to claim 4, wherein said antibodies are humanized.
8. The method according to claim 1, wherein the antibodies are administered at a dose of from 0.25 to 25 mg/kgbodyweight.
9. The method according to claim 8, wherein the antibodies are administered at a dose of from 1 to 20 mg/kgbodyweight.
10. The method according to claim 8, wherein the antibodies are administered at a dose of from 7 to 15 mg/kgbodyweight.
11. The method according to claim 8, wherein the antibodies are administered at a dose of from 8 to 12 mg/kgbodyweight.
12. The method according to claim 1 wherein said antibodies are administered as a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient.
13. The method according to claim 12 wherein said pharmaceutical composition is comprised within a kit.
14. The method according to claim 3, wherein said antibodies are chimeric.
15. The method according to claim 5, wherein said antibodies are humanized.
16. The method according to claim 7, wherein the antibodies are administered at a dose of from 0.25 to 25 mg/kgbodyweight.
17. The method according to claim 7, wherein the antibodies are administered at a dose of from 8 to 12 mg/kgbodyweight.
18. The method according to claim 15, wherein the antibodies are administered at a dose of from 0.25 to 25 mg/kgbodyweight.
19. The method according to claim 15, wherein the antibodies are administered at a dose of from 1 to 20 mg/kgbodyweight.
20. The method according to claim 15, wherein the antibodies are administered at a dose of from 8 to 12 mg/kgbodyweight.
US18/317,076 2022-02-10 2023-05-13 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof Pending US20230331842A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/317,076 US20230331842A1 (en) 2022-02-10 2023-05-13 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP22156205 2022-02-10
EP22156205.1A EP4227321A1 (en) 2022-02-10 2022-02-10 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
US18/161,070 US20230272073A1 (en) 2022-02-10 2023-01-29 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
US18/317,076 US20230331842A1 (en) 2022-02-10 2023-05-13 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US18/161,070 Continuation US20230272073A1 (en) 2022-02-10 2023-01-29 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Publications (1)

Publication Number Publication Date
US20230331842A1 true US20230331842A1 (en) 2023-10-19

Family

ID=80446495

Family Applications (2)

Application Number Title Priority Date Filing Date
US18/161,070 Pending US20230272073A1 (en) 2022-02-10 2023-01-29 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
US18/317,076 Pending US20230331842A1 (en) 2022-02-10 2023-05-13 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US18/161,070 Pending US20230272073A1 (en) 2022-02-10 2023-01-29 Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Country Status (4)

Country Link
US (2) US20230272073A1 (en)
EP (2) EP4227321A1 (en)
JP (2) JP7401161B2 (en)
KR (1) KR20230121579A (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1068241E (en) 1998-04-02 2007-11-19 Genentech Inc Antibody variants and fragments thereof
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
US20110190157A1 (en) * 2008-08-15 2011-08-04 The Regents Of The University Of California Biomarkers for Diagnosis and Treatment of Chronic Lymphocytic Leukemia
EP3424527A1 (en) 2017-07-07 2019-01-09 AVA Lifescience GmbH Diagnostic method
JP2022514423A (en) * 2018-12-20 2022-02-10 アー・ファウ・アー ライフサイエンス ゲー・エム・ベー・ハー Method for selecting biologically bound molecules
CN113784756A (en) * 2019-05-02 2021-12-10 阿瓦生命科学有限公司 Biological binding molecules

Also Published As

Publication number Publication date
JP7401161B2 (en) 2023-12-19
US20230272073A1 (en) 2023-08-31
KR20230121579A (en) 2023-08-18
EP4227321A1 (en) 2023-08-16
EP4227322A1 (en) 2023-08-16
JP2023117408A (en) 2023-08-23
EP4227321A8 (en) 2023-09-27
JP2024023511A (en) 2024-02-21

Similar Documents

Publication Publication Date Title
KR102379464B1 (en) anti-PD-L1 antibody
CA2525251C (en) Cd20-specific antibodies and methods employing same
ES2929575T3 (en) therapeutic antibodies
KR101671039B1 (en) Anti CXCR4 antibodies and their use for the treatment of cancer
JP7282401B2 (en) Use of Anti-FAM19A5 Antibodies for Cancer Therapy
JP2023134490A (en) Neutralization of inhibitory pathways in lymphocytes
CN117098561A (en) CCR8 antibodies and uses thereof
CN112513080A (en) VISTA antigen binding molecules
JP2019517993A (en) Anti-MICA antibody
WO2020151762A1 (en) Novel bispecific antibody molecule and bispecific antibody simultaneously combining pd-l1 and lag-3
KR20210142638A (en) CD3 antigen-binding fragment and applications thereof
WO2020151761A1 (en) Bispecific antibody binding to pd-l1 and ox40
KR20220062500A (en) Anti-CD39 Antibody Compositions and Methods
JP2023055904A (en) Multispecific antibodies in combination therapy for cancer immunotherapy
AU2021297856A1 (en) Anti-CD73 antibody and use thereof
JP2023530003A (en) Anti-Claudin18.2 antibody and uses thereof
WO2023152204A9 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
WO2022223004A1 (en) Anti-siglec-15 antibody and use thereof
US20230331842A1 (en) Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof
CN112969715B (en) anti-CD 47 antigen binding protein and application thereof
CN115521378B (en) PD-L1 antibodies and uses thereof
CN114437215B (en) Anti-human CD38 antibody and preparation method and application thereof
CN115521379B (en) PD-1 antibodies and uses thereof
US20240084014A1 (en) Multispecific binding compounds that bind to pd-l1
WO2024023124A1 (en) Humanized chimeric antigen receptors targeting the b-cell receptor of chronic lymphocytic leukemia and uses thereof

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION